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Endothelial Heat Shock Protein A12B and Yes-associated Protein Cooperatively 






Heart failure after myocardial infarction (MI) remains the leading cause of mortality 
among all cardiovascular diseases globally. Angiogenesis plays a critical role in cardiac 
functional recovery after MI. Heat shock protein A12B (HSPA12B) is predominately 
expressed in endothelial cells and required for angiogenesis. Yes-associated protein 
(YAP) has been reported to promote tumor angiogenesis. 
 
In the present study, we investigated the cooperative role of HSPA12B and YAP in 
angiogenesis following myocardial ischemic injury. Endothelial specific deficiency of 
HSPA12B (eHspa12b-/-) or YAP (eYap-/-) impairs angiogenesis and exacerbates cardiac 
dysfunction after MI, when compared with wild type (WT) mice. In addition, MI induced 
angiogenesis and the expression of angiogenic factors (angiopoietin-1, VEGF and 
VEGFR2) were impaired in both eHspa12b-/- and eYap-/- hearts. MI increased YAP 
expression and nuclear translocation in WT hearts, but not in eHspa12b-/- myocardium. 
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Similarly, MI also markedly increased HSPA12B expression and nuclear translocation in 
WT mice but not in eYap-/- hearts.  
 
In vitro data shows that overexpression of HSPA12B upregulated hypoxia induced 
endothelial cell proliferation, migration and angiogenesis. On the contrary, deactivation 
of YAP by verteporfin attenuates endothelial cell proliferation, migration and 
angiogenesis after hypoxic challenge. In accordance, silencing of either HSPA12B or 
YAP suppressed endothelial cell proliferation and angiogenesis promoted by hypoxia. 
Importantly, YAP inhibition abrogates HSPA12B induced endothelial cell proliferation 
and angiogenesis. Deficiency of HSPA12B suppresses YAP expression and nuclear 
translocation following hypoxia while knockdown of YAP attenuates hypoxia stimulated 
HSPA12B expression and nuclear translocation. 
 
Mechanistically, hypoxia induced an interaction between endothelial HSPA12B and 
YAP. Of note, ChIP assay shows that HSPA12B is a target gene of YAP/transcriptional 
enhanced associated domain 4 (TEAD4). Further investigation indicates that HSPA12B 
also acts as a co-activator in YAP associated proliferation and angiogenesis. HSPA12B 
can stabilize YAP and prevent YAP from degradation. 
 
Therefore, our results delineated a previously unrecognized role of endothelial 
HSPA12B as a novel target and co-activator for YAP/TEAD4 and cooperates with YAP 
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CHAPTER 1. INTRODUCTION 
 
Myocardial Infarction and Angiogenesis 
 
Overview and Definition 
 Although tremendous efforts have been made to find novel therapies in 
the last two decades, cardiovascular diseases continue to be the leading cause of 
mortality worldwide 1-3. According to World Health Organization (WHO), cardiovascular 
diseases are the number one killer globally, taking about 17.9 million lives annually 
(https://www.who.int/health-topics/cardiovascular-diseases). In the United States, about 
92.1 million adults are affected with cardiovascular diseases and about 655,000 
Americans die from cardiovascular diseases each year, making it account for 1 in 4 
deaths 1. Heart failure after myocardial infarction (MI) remains the leading cause of 
mortality among all cardiovascular diseases 1; 4. Each year about 805,000 
Americans have a MI. Of these, 605,000 are a first MI and 200,000 happen in people 
who have already had a MI 5.  
 
MI, which is also known as heart attack, develops when the flow of oxygen-rich 
blood to myocardium suddenly becomes blocked and the heart cannot get the oxygen. 
Formation of a thrombus in a coronary vessel induced by atherosclerotic plaque rupture 
is the main reason that causes the blockage 6; 7. If the infarction is not treated quickly, 
the portion of myocardial cells begin to die, resulting in permanent heart damage. Once 
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myocardial necrosis happens in accord with myocardial ischemia, we define it MI by 
pathology and clinical 8.  
 
Pathophysiology of MI 
In the adult heart, mitochondrial oxidative phosphorylation of cardiac myocytes 
produces almost all the adenosine triphosphate (ATP) required for cardiac pump 
function 9. During myocardial ischemia, the aerobic function of mitochondria and its 
ability to generate ATP are disrupted significantly. Meanwhile, insufficient oxygen 
induces anaerobic glycolysis in cardiomyocytes, which is the primary source of new 
ATP production. However, only limited ATP is produced in this way and lactate, the end 
product of glycolysis, prevents further generation of ATP by inhibiting important 
enzymes of the glycolytic pathway 10; 11. As a result, about 15-20 minutes after ischemia, 
glycolysis will be disrupted markedly and the energy storage of the myocardium will be 
depleted. In addition, ischemia also causes profound consequences including 
intracellular acidosis, efflux of potassium (K+) from the intracellular to extracellular 
space, increases in intracellular sodium (Na+) and cytosolic calcium (Ca2+), generation 
of reactive oxygen species (ROS) and so on. Previous studies have shown that 
induction of ROS and cytosolic calcium contributes to cardiac cell apoptosis, necrosis 
and autophagy after MI 12. Necrosis of cardiac myocytes triggers inflammatory 
responses through activation of toll-like receptor (TLR), interlukin (IL)-receptor 
dependent signaling pathways following MI, leading to the induction of a transcription 
factor, nuclear factor (NF)-κB 12; 13. Our group have reported the essential role of NF-κB 
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system in the development of heart failure during cardiac hypertrophy, MI and cardiac 
ischemia/reperfusion (I/R) 14-16. 
 
Cardiac Remodeling Following MI 
Regardless of causes, cardiac remodeling is primarily responsible for adaptive 
and maladaptive changes in cardiac shape, structure, metabolism and function in 
response to pressure overload (e.g. hypertension), volume overload (e.g. valvular heart 
disease), MI, dilated cardiomyopathy and inflammatory heart disease (e.g. myocarditis) 
17-20. Maladaptive cardiac remodeling, an unavoidable event in response to almost all 
cardiac injuries including MI, is generally accepted as a determinant of the development 
of heart failure and other severe consequences. Initially, cardiac remodeling after MI 
might be beneficial for recovery at the early stage of the healing process. Reparative 
cardiac fibrosis is crucial for preventing MI-induced rupture of the ventricular wall 21. 
Conversely, reactive fibrotic response, characterized with extracellular matrix (ECM) 
expansion, compromises diastolic function and normal electrical function of the heart, 
and, eventually, leads to heart failure 21; 22. In ischemic hearts, oxygen depletion induces 
proliferation of endothelial cells and regenerative angiogenesis 23. In addition, hypoxia-
mediated necrosis and cell death recruit immune cells in the infarcted tissue to promote 
the replenishment of cardiomyocytes and restore cardiac function 24. However, 
uncontrolled infiltration of inflammatory cells may place increased burden on reperfusion 
injury 25. Therefore, more investigations are required to understand the detailed 
mechanisms of cardiac remodeling, thereby improving cardiac function after cardiac 
ischemic injury and preventing the transition to heart failure. 
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The Role of Angiogenesis in MI 
Angiogenesis is a process of forming new blood vessels from existing 
microvessels 26. It plays an important role in organ growth and development. Recent 
investigations also show evidence that therapeutic neovascularization improved 
outcome in myocardial ischemia 27-29, indicating the positive role of angiogenesis in 
cardiac remodeling after cardiac injuries.  
 
MI induces the release of different kinds of angiogenic growth factors, including 
angiopoietin-1 and -2 (Ang-1 and -2), vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), basic epidermal growth factor (bEGF), platelet-derived 
growth factors, transforming growth factors and so on, leading to the activation of 
myocardial angiogenesis 30-33. Among these pro-angiogenic factors, VEGF and Ang-1 
are major regulators of angiogenesis 34.  
 
VEGF takes a critical part in the formation of novel capillaries in different organs 
as well as neovascularization following cardiac injury 35. There are 5 members in the 
VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor 36-39. 
Among these, VEGF-A is the initially described VEGF, which has been studied most for 
its ability in forming blood vessels 37; 38. In response to cardiac ischemia, the expression 
of hypoxia-inducible factor1-α (HIF1-α) is upregulated, leading to an increase in VEGF-
A 32. VEGF-A interacts with 2 receptors: VEGF receptor1 (VEGFR1) and VEGF 
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receptor2 (VEGFR2), of which VEGFR2 is responsible for the induction of angiogenesis 
40.  
 
Besides VEGF signaling, angiopoietin activation is considered as the second 
most crucial pathway during angiogenesis 41-44. Among 4 members in the angiopoietin 
family, the role of Ang-1 and Ang-2 are well studied. Ang-1 can bind to its receptor Tie2, 
which is mainly expressed in endothelial cells, thereby regulating endothelial cell 
function and promoting angiogenesis 45; 46. Inhibition of either Ang-1 or Tie2 is 
embryonic lethal 45; 47. The role of Ang-2 is more complicated. In most conditions, Ang-2 
suppresses the function of Ang-1 and works as an antagonist for Tie2 46; 48. Conversely, 
several investigations have shown that Ang-2 can also activate endothelial 
angiogenesis under certain circumstances 46; 49; 50. 
 
Tao and colleagues found that co-injection of adeno-associated viral vectors 
(AAVs) expressing VEGF and Ang-1 in pigs promoted myocardial angiogenesis and 
cardiac myocyte proliferation after MI, thereby improving cardiac function 51. On the 
contrary, suppression of VEGF signaling impaired cardiac angiogenesis, resulting in 
early transition to heart failure 52. Despite a promising intervention in these preclinical 
studies, use of angiogenic factors, such as VEGF and bEGF for MI did not provide 
favorable results in the clinic 26; 40; 53. In order to develop novel and efficient approaches 
for the treatment of MI, there is a great need for a comprehensive understanding of the 
mechanisms of angiogenesis in ischemic hearts.  
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 The Functions of Endothelial Cells in the Heart 
 
The Role of Endothelial Cells in Adherens Junction, Tight Junction and Vascular 
Permeability 
Endothelium is a natural biological barrier between circulating blood and 
underlying organs 54; 55. In the past, it was believed to be an inert barrier. However, 
accumulating evidence shows that the endothelium serves as a distributed organ and 
displays distinct immunological and metabolic functions in different tissues 56; 57. As one 
of the most abundant cell types in cardiac cells, endothelial cells are essential for 
supporting cardiac contractile function, regulating vascular tone and permeability under 
normal conditions 58; 59. Adherens junction and tight junction of endothelial cells play a 
critical role in maintaining organ shape. Platelet endothelial cell adhesion molecule-1 
(PECAM-1) and vascular endothelial cadherin (VE-cadherin) are important adherens 
molecules that can form and maintain endothelial cell connection and stability 60; 61. 
Additionally, claudins and occludin together with zonula occludens (ZOs) including ZO-
1, ZO-2, ZO-3 form complexes to regulate endothelial cell tight junction 62. 
 
In the dynamics of cardiovascular pathology, endothelial cell dysfunction 
contributes to vascular damage, thereby resulting in cardiac injury 57; 63; 64. For example, 
myocardial ischemia induced endothelial cell swelling and inflammation leads to heart 
tissue edema 40. Following ischemia, hypoxia disrupts endothelial cell adherens junction 
and tight junction, increases vascular permeability and causes vascular diseases 65; 66. 
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According to Graesser and colleagues, in the absence of PECAM-1, vascular 
permeability was increased in the mouse 67. Gao et al reported that cardiac I/R 
diminished the expression of VE-cadherin in the heart and induced cardiac necrosis 68. 
In addition, decreasing of Claudin5, the primary component of tight junctions, was found 
to contribute to cardiac microvascular hyperpermeability in diabetes 69. Insufficient 
expression of another tight junction molecule, ZO-1, disrupted endothelial cell-cell 
connection and increased endothelial permeability 70. 
 
The Role of Endothelial Cells in Cardiac Angiogenesis 
Endothelial cells have been reported to participate in myocardial angiogenesis 
after cardiac ischemia 27; 40. Stimulation of endothelial cells to the proliferative and 
migratory phenotypes are essential for angiogenesis 26; 53; 71. The receptors of many 
growth factors such as VEGF and Ang-1 are expressed on endothelial cells. As 
mentioned above, hypoxia induced HIF1-α signaling can promote growth factor release, 
thus facilitating endothelial cell proliferation and migration as well as tube formation 
ability 32; 72. In addition, hypoxia can also promote endothelial cell proliferation and 
subsequent vascular remodeling via mammalian target of rapamycin (mTOR)/threonine-
protein kinase (Akt) signaling pathway 73. Specifically, silencing mTORC1 interrupted 
endothelial cell proliferation in the early stage of hypoxia (< 3 hours) while inhibition of 
mTORC2 suppressed endothelial cell proliferation 3 hours after hypoxia through 
occluding the phosphorylation of Akt. Activation of Akt has been found to induce 
neovascularization and inhibit endothelial cell apoptosis in response to cardiac ischemia 
74. Moreover, Dufourcq and colleagues discovered that the Wnt/frizzled pathway also 
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participated in endothelial cell angiogenesis 75. A secreted frizzled related protein FrzA 
increases endothelial cell migration and differentiation and acts as a pro-angiogenic 
factor through blocking Wnt/frizzled signaling. 
 
Adherens junction proteins including PECAM-1 and VE-cadherin have been 
reported to participate in endothelial cell angiogenesis as well 76. As the most prominent 
cadherin, VE-cadherin can interact with VEGFR2 to promote angiogenesis through 
regulating phosphoinositide 3-kinase (PI3K) signaling 77; 78. Even though inactivation of 
PECAM-1 did not show vascular changes in the embryo 79, inhibition of PECAM-1 
suppressed endothelial cell tube formation and decreased adult murine angiogenesis 80. 
 
The Role of Endothelial Cells in Cardiac Immunity 
TLRs are surface receptors known for their important role in regulating innate 
immune responses 81. Previous studies from our group and others have shown that 
TLR2, TLR3, TLR4 and TLR9 all participated in modulating cardiac function following 
different injuries including MI, I/R, cardiac hypertrophy and so on 82-86. Importantly, 
these TLRs are expressed on endothelial cell surfaces, and promote the activation of 
endothelial cells in response to stimulation such as lipopolysaccharide (LPS) 87. In 
addition to the above functions, activated endothelial cells also secrete cytokines, 
chemokines and growth factors as well as regulate immune cells to protect the heart 
against injury 63; 88. For example, we have found that endothelial cells are able to 
secrete tumor necrosis factor-α (TNF-α) and interlukin-1β (IL-1β) after hypoxic 
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challenge, leading to the transition of macrophages toward pro-inflammatory phenotype 
(data not published). Interestingly, macrophages can also regulate endothelial cell 
angiogenesis by inducing pro-angiogenic factors and increasing vascular remodeling 89. 
 
Moreover, in the presence of stimuli, the expression of adhesion molecules 
including intercellular adhesion molecular-1 (ICAM-1) and vascular cell adhesion 
molecular-1 (VCAM-1) are upregulated in endothelial cells, which would increase 
leukocyte emigration and lead to the generation of further inflammatory and immune 
responses 63; 90. We recently found that cecal ligation and puncture (CLP) significantly 
upregulated the expression of ICAM-1 and VCAM-1 in the myocardium, resulting in the 
infiltration of neutrophil and macrophage 91. Therefore, improving endothelial cell 
function is of great importance in regulating cardiac inflammation and immune 
responses.  
 
Heat Shock Protein A12B 
 
Heat Shock Proteins 
Heat shock proteins (HSPs) are highly conserved molecular chaperones that can 
be produced by different stresses such as heat shock, wound healing, ischemia, 
hypoxia and inflammation 92; 93. HSPs are widely distributed in mammalian cells and 
classified by their molecular weight, among which HSP60, HSP70 and HSP90 families 
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are most well-studied 94. As chaperones, HSPs play an essential role in protein-protein 
interactions including regulating protein folding and misfolding, protein assembly and 
disassembly 95; 96. Extensive investigation has revealed that HSPs play a role in 
cardiovascular diseases 97-99. For instance, overexpression of HSP20, attenuated I/R 
induced cardiac dysfunction and necrosis through increasing the ratio of Bcl-2/Bax and 
reducing cardiac myocyte apoptosis 98. HSPs also display an important role in 
regulating endothelial cell function and angiogenesis 100. 
 
HSP70 and Its Cardiovascular Role 
The HSP70 family is the most ubiquitous group of HSPs with molecular weights 
from 65kDa to 80kDa. In response to cardiac stress such as hypertrophy and infarction, 
the expression of HSP70 is upregulated. HSP70 transgenic mice show a protective role 
after ischemia 101; 102. Hypoxia induced expression of HSP70 improves rat cardiac 
function post-I/R 103. In accordance, Marber et al found that upregulation of HSP72, a 
member of HSP70 family, protected against cardiac dysfunction and decreases infarct 
size after MI in rabbit heart 104. In vitro study showed that suppress of HSP72 induced 
cardiomyocyte damage and death following hypoxic challenge 105. Further investigation 
uncovered that PI3K/AKT signaling contributed to the increase of HSP70 in ischemic 
heart 106. Blockage of HSP70 induced cardiac myocyte apoptosis through activation of 
c-Jun N-terminal kinases (JNK) and suppression of Fas signaling during I/R 107; 108. 
Recently, HSP70 is detected in exosomes and exosomal HSP70 plays a myocardial 
protective role through the activation of Toll-like receptor4 (TLR4) pathway 109. In 
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addition to animal studies, circulating HSP70 levels are recognized as an indicator for 
bad outcomes in patients with heart diseases 110; 111.  
 
The Discovery and Function of HSPA12B 
In 2003, Han and colleagues first discovered HSPA12 in atherosclerotic lesions, 
consisting of two isoforms, HSPA12A and HSPA12B 112. HSPA12A and HSPA12B 
belong to the HSP70 family. However, unlike other HSP70 proteins which are widely 
expressed in different types of tissues and cells, HSPA12B is mainly expressed in 
vascular endothelium 113. Further in vitro studies revealed that HSPA12B is required for 
angiogenesis through regulating endothelial cell migration and adhesion 113; 114. In 
addition, suppression of HSPA12B in zebrafish resulted in incomplete and disrupted 
vascular development 114.  
 
To date, several pieces of evidence investigate the function of HSPA12B in 
cardiovascular diseases. Overexpression of HSPA12B improves cardiac dysfunction 
and ventricular remodeling following MI and endotoxin induced sepsis via promoting 
endothelial nitric oxide synthase (eNOS)-dependent signaling and reversing LPS 
induced inactivation of PI3K/Akt signaling 115; 116. Similarly, HSPA12B showed a 
protective role in cerebral stroke by inducing angiogenesis through upregulating eNOS 
expression 117. HSPA12B also attenuated cerebral cell apoptosis by preventing 
phosphorylation of JNK, extracellular signal regulated kinase (ERK), p38 and promotes 
blood-brain-barrier (BBB) integrity by inducing phosphorylation of Akt and glycogen 
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synthase kinase-3β (Gsk-3β) 118. However, the mechanism by which HSPA12B 
regulates PI3K/Akt signaling remains unclear. We recently constructed endothelial cell 
specific Hspa12b knockout mice and discovered that absence of endothelial HSPA12B 
causes higher mortality and enhanced cardiac dysfunction after CLP induced sepsis 
when compared with wild type (WT) mice 91. Subsequent study showed that blockade of 
HSPA12B increased the expression of ICAM-1 and VCAM-1, leading to the infiltration of 
macrophages and neutrophil. On the contrary, overexpression of HSPA12B attenuated 
LPS induced endothelial cell ICAM-1 and VCAM-1 upregulation. We also found that 
HSPA12B upregulated microRNA-126 levels. Delivering exosomes containing 
microRNA-126 improved cardiac function and reduced adhesion molecule expression in 
HSPA12B knockout septic mice, indicating that HSPA12B regulates sepsis mediated 
cardiac dysfunction via controlling the levels of microRNA-126. Another study shows 
that LPS induced expression of microRNA-4505 could interact with HSPA12B and 
downregulate the expression of HSPA12B, resulting in endothelial cell dysfunction 119.  
 
Besides cardiovascular diseases, HSPA12B is also found to protect against lung 
injury after sepsis by improving endothelial cell function 120; 121. Overexpression of 
HSPA12B attenuates pulmonary injuries including increased neutrophil infiltration and 
vascular permeability induced by LPS through inhibiting the activation of ERK and 
cyclooxygenase-2 (Cox-2) 120. Conversely, knockdown of HSPA12B increased mortality 
and pulmonary edema in CLP sepsis 121. The underlying mechanisms might be the 
phosphorylation of ERK and pulmonary endothelial cell apoptosis induced by 
knockdown of HSPA12B. In septic patients, the plasma levels of HSPA12B were higher 
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than those in volunteers and other septic patients, indicating that HSPA12B might be 




The Hippo/Yes-associated Protein Pathway 
The Hippo/yes-associated protein (YAP) pathway is a highly conserved signaling 
cascade that plays a critical role in organ development and tissue homeostasis 123-126. 
Because of its function in cell metabolism, proliferation and apoptosis, dysregulated 
Hippo/YAP signaling is associated with various human diseases including 
cardiovascular diseases. Adult human hearts have limited ability to repair themselves 
following cardiac injuries 127; 128. Recently, a large body of evidences show that 
Hippo/YAP signaling regulates heart development and could be potential modulator of 
several remodeling process after cardiac injury 128-131, which might be a new therapeutic 
target in controlling injury-mediated cardiac remodeling and improving the outcome of 
cardiovascular diseases. 
 
Since the first report of Hippo signaling in Drosophila, intensive interest in this 
pathway has led to rapid increase in our understandings of its functions and regulations 
in both Drosophila and mammals. In mammals, the Hippo signaling is comprised of 
serine/threonine kinases mammalian sterile 20-like kinase1/2 (MST1/2) and large tumor 
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suppressor kinase1/2 (LATS1/2), and scaffold proteins salvador1 (SAV1) and mps one 
binder kinase activator-like 1 (MOB1) 127; 128. YAP and transcriptional co-activator with 
PDZ-binding motif (TAZ, also known as WWTR1) are the primary downstream effectors 
of the Hippo pathway. 
 
As shown in Figure 1, when Hippo signaling is activated, MST1/2 accompanied 
with SAV1 phosphorylates and activates the LATS1/2-MOB1 complex, leading to the 
phosphorylation and inactivation of YAP and TAZ. There are two main phosphorylation 
sites of YAP, serine 127 (S127) and serine 397 (S397) 128; 131-135. Phosphorylation of 
S127 gives rise to the combination of YAP and 143-3-3, thus localizing it in the 
cytoplasm while phosphorylation of S397 promotes the ubiquitination and degradation 
of YAP. 14-3-3 proteins are a highly-conserved family of homo- or heterodimers that 
play an important role in multiple cellular processes by interacting with other molecules. 
In contrast, when Hippo signaling is off, MST1/2-SAV1 inactivation prohibits 
phosphorylation and activation of LATS1/2-MOB1, which triggers YAP/TAZ 
dephosphorylation and activation. Activated YAP/TAZ translocate to the nucleus and 
bind to several transcription factors including transcriptional enhancer associated 




Figure 1. Hippo signaling “on” and Hippo signaling “off”. a, When Hippo signal is 
activated, YAP/TAZ is phosphorylated and remains in the cytoplasm by binding to 14-3-
3 or it is degraded. b, When Hippo signal is inhibited, YAP/TAZ is activated and 
translocated to nucleus. Nuclear YAP/TAZ associates with TEAD to activate target 
genes that are related to cell proliferation, apoptosis and angiogenesis. Hippo signaling 
crosstalks with several different signaling. Hippo signaling activates MAPK signaling. 
AMPK activation leads to YAP activation. YAP activation results in PI3K-AKT activation 
and Wnt signaling inactivation. 
 
The Role of YAP in Cardiovascular Disease 
 Hippo/YAP regulates cardiomyocyte hypertrophy and apoptosis. The Hippo/YAP 
signaling pathway has been reported to regulate cardiac hypertrophy 136-141. In 2003, 
Yamamoto et al first reported that activation of MST1 is required for a novel kind of 
dilated cardiomyopathy by stimulating cardiomyocyte apoptosis, but negatively 
regulating cardiac hypertrophy via activation of p38-mitogen-activated protein kinases 
(MAPK) and JNK-MAPK in myocardial cells 136. Both the upstream activator of MST1, 
ras-association domain family 1 isoform A (RASSF1A) and downstream kinase of 
MST1, LATS1, negatively regulate neonatal rat ventricular myocyte hypertrophy 
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following mechanical stress via paracrine secretion of TNF-α and IL-1β by neonatal rat 
cardiac fibroblasts 138; 139. As a core effector of Hippo pathway, YAP has been 
demonstrated to promote cardiac myocyte hypertrophy and suppress apoptosis 142. In 
addition, cardiac-specific activation of YAP attenuates cardiac I/R induced 
cardiomyocyte apoptosis via crosstalk with FoxO1, which also plays a key role in cell 
proliferation and apoptosis 143. On the contrary, Lin et al reported that constitutive 
overexpression of YAP in murine heart failed to induce cardiac hypertrophy within four 
months in their in vivo study 131. Bergmann and colleagues revealed that activation of 
YAP promoted cardiomyocyte proliferation, while overexpression of YAP had no 
hypertrophic effects on cardiomyocytes, which raises questions controversial about the 
involvement of Hippo/YAP signaling in hypertrophic growth of cardiomyocytes 144. 
Together, although there is a debate about the function of YAP in cardiac myocytes, 
solid evidence from different groups suggests a potential function of YAP in regulating 
hypertrophy and apoptosis of cardiomyocyte through modulation of MAPK activation 
and paracrine of cardiac fibroblasts. 
 
 Hippo/YAP regulates cardiomyocyte proliferation. Although cardiomyocytes have 
little capacity to proliferate, more and more research provides evidence of potential 
cardiomyocyte proliferation in murine and human hearts 144-146. The essential role of 
YAP in cardiac myocyte renewal could lead to cardiac regeneration, which may 
generate new therapies for cardiac injuries. In the embryonic stage, inhibition of the 
Hippo cascade by specific knockout of Sav1, Mst1/2 or Lats2 could activate YAP, thus 
elevating cardiac myocyte proliferation without enhancing the number of other types of 
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cardiac cells 137. The underlying mechanism might be the interaction of YAP with Sox2 
and Snai2 genes of β-catenin of Wnt pathway. Direct knockout of cardiomyocyte-
specific Yap1 shows insufficient cardiomyocyte proliferation, leading to fatal cardiac 
hypoplasia 147; 148. Activation of YAP1 promotes both fetal and neonatal cardiomyocyte 
proliferation via interaction of YAP1 and TEAD 147 and activation of insulin-like growth 
factor (IGF)-dependent PI3K/AKT signaling, thereby suppressing Wnt-β-catenin 
signaling 148. By interaction with TEAD, YAP directly promotes the activation of Pik3cb, 
which is an important connection between Hippo/YAP and PI3K-AKT signaling, leading 
to the proliferation of neonatal myocardial cells 149. In addition, in response to 
ischemia/reperfusion of newborn mice, glycolysis-prohibited activation of LATS and 
AMP-activated protein kinase (AMPK) would induce the activation of YAP1, resulting in 
neonatal cardiomyocyte proliferation by regulating miR-152 128. In adult mouse heart, 
activation of YAP also stimulates cardiac myocyte proliferation and improves survival 
rate following MI 130; 131 at least partly through regulating IGF1 and AKT signaling 130. A 
recent study shows another gene, paired-like homeodomain transcription factor 2 
(Pitx2), is able to regulate both neonatal and adult cardiomyocyte proliferation after 
cardiac injury through crosstalk with YAP 150. In conclusion, all these studies indicate 
that YAP regulates cardiomyocyte proliferation through interacting with IGF-dependent 
PI3K-AKT signaling and Wnt-β-catenin signaling, which is essential in cardiac 
regeneration after injuries. 
 
 Hippo/YAP regulates fibroblast activation. Several studies have provided 
evidence for the involvement of Hippo/YAP signaling in pressure overload or MI induced 
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fibrosis 130; 138; 141; 142. Work of Mei Xin and colleagues showed that constitutive 
expression of cardiac YAP prevented cardiac fibrosis and improved survival post-MI 
both in neonatal and adult hearts partly via activating IGF1-dependent AKT signaling 
130. Conversely, inhibiting the expression of YAP led to more severe fibrosis induced by 
MI 142. Cardiac fibroblasts are the main cells that are responsible for the development of 
cardiac fibrosis 146. Comprising an essential population in heart, myofibroblasts are 
considered to originate from epicardium during heart development 151. Progenitor cells 
in the epicardium undergo a series of transition states, and eventually differentiate into 
mature cardiac fibroblasts. A recent study showed that LATS1/2 is required for the 
transition from progenitor cells to fully-differentiated cardiac fibroblasts in embryonic 
developing heart through down-regulating downstream YAP target Dhrs3 and up-
regulating Dpp4 152. Dhrs3 is an inhibitor of retinoid signaling that suppresses fibroblast 
differentiation while Dpp4 is a protease that induces ECM composition 152.  
 
In the adult heart, cardiac fibroblasts remain in a ‘quiescent’ state with limited 
proliferation. However, during cardiac injuries, fibroblasts are recruited to the injury site 
and become activated. Inhibited activity of YAP/TAZ significantly reduced disposition of 
ECM proteins and attenuated fibrosis in damaged kidney 153. A previous study of our 
group showed that increased activity of LAST1 and inhibited YAP expression, by the 
administration of the Toll/interleukin-1 receptor (TIR)/BB-loop mimetic AS-1, could 
reduce proliferation and differentiation of cardiac fibroblasts at least partly through 
phosphorylation of JNK-MAPK 139. Therefore, Hippo/YAP is involved in maintaining the 
activation of cardiac fibroblasts and cardiac injury-induced fibrosis. 
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 Hippo/YAP regulates cardiac immune cells. As in most tissues, cardiac injuries 
rapidly activate the inflammatory reactions, including innate and adaptive immune 
responses, to mediate tissue growth and repair 154-156. The primary immune cells that 
reside in heart are macrophages, which are crucial players in homeostatic maintenance 
of myocardium at steady state 157. Aside from cardiac macrophages, resident arterial 
macrophages are important cellular components in maintaining homeostasis of 
cardiovascular system and regulating repair after cardiac injuries 158-160. One prominent 
function of the arterial macrophage is in pathogenesis of vulnerable plaques in 
atherosclerosis 159; 160. During early stage of atherosclerotic plaques, clearance of 
apoptotic cells by macrophage autophagy efficiently contributes to stabilization of 
plaques and attenuates the progress of atherosclerosis 161. Unfortunately, in advanced 
atherosclerosis, autophagy is defective. Recently, increased MST1 phosphorylation and 
expression of MST1, an upstream kinase of YAP, were observed in atherosclerotic 
plaques by Wang et al 162. Constitutive depletion of MST1 rescued mice from 
atherosclerosis, accompanied by a decreased atherosclerotic area. Importantly, 
knockdown of MST1 decreased, while overexpression of MST1 increased, apoptosis of 
macrophage upon ox-LDL exposure 162.  
 
Over-activated and prolonged inflammation results in adverse cardiac remodeling 
after MI. Previous studies by several groups suggested that regulatory T cells (Treg 
cells), a subset of CD4+ T cells, suppress immune-mediated inflammation following MI 
163; 164. Vimal Ramjee et al revealed epicardium YAP/TAZ is required in the recruitment 
of Treg cells following MI 165. Less suppressive Treg cells were observed in the infarct 
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tissues after deletion of epicedial Yap and Taz, accompanied with upregulated 
inflammatory responses and fibrosis. Interestingly, activated Treg cells enable an 
improved healing after MI by modulating macrophage differentiation into anti-
inflammatory phenotype (M2-like macrophage) 166. 
 
 Hippo/YAP regulates endothelial cell angiogenesis. Recently, several studies 
implicated YAP in cancer cell angiogenesis 167; 168. Firstly, Calvo et al reported that 
depletion of Yap reduced the ability of cancer associated fibroblasts to promote 
angiogenesis in vivo 167. In human cholangiocarcinoma (CC) and CC xenografts, YAP 
has been claimed to promote angiogenesis by regulating proangiogenic microfibrillar-
associated protein 5 (Mfap5) expression in a TEAD dependent manner 168. In addition, 
there are indications that endothelial YAP/TAZ is required for vascular network 
formation in brain through activation of Cdc42, myosin light chain-2 (MLC2) and MYC 
signaling, which are able to regulate endothelial cell proliferation, migration, metabolism 
and junction assembly 169. Although Hippo/YAP has been revealed as a critical player 
during cardiac regeneration and repair in the last decade, studies focused exclusively 
on its regulatory effects on cardiomyocytes or fibroblasts in the context of either cardiac 
hypertrophy or infarction. Whether YAP is involved in angiogenesis during cardiac 





Hypothesis and Specific Aims 
 
In the present study, we investigated the molecular mechanisms by which 
endothelial HSPA12B, cooperatively with YAP, regulates endothelial cell function and 
angiogenesis following MI. Moreover, we disclosed how ischemic injury or hypoxia 
induces the expression of HSPA12B and YAP. There are 3 specific aims in our study. 
 Aim 1: Identify the angiogenic role of endothelial cell HSPA12B following 
MI and hypoxic challenge. The findings are presented in Chapter 2 and 3. 
Aim 2: Investigate the role of endothelial cell YAP in angiogenesis 
following MI and hypoxic challenge. The findings are presented in Chapter 4. 
Aim 3: Determine the novel mechanisms by which HSPA12B and YAP work 
together to regulate endothelial cell angiogenesis. The findings are presented in 





CHAPTER 2. ENDOTHELIAL CELL HSPA12B IS REQUIRED FOR MAINTAINING 





Angiogenesis plays a key role in improving cardiac function after MI by improving 
revascularization and blood flow in long-term left ventricular remodeling 26; 58. Therefore, 
it is a potential target for the development of therapeutic approach to treat ischemic 
myocardium. Mounting evidence has shown that activation of several growth factors 
including VEGF, bFGF, Ang-1 and bEGF can promote endothelial angiogenesis in 
animal models 27; 170-172. In addition, some angiogenic factors such as sonic hedgehog 
can stimulate angiogenesis indirectly by upregulating the expression of VEGF and other 
growth factors in response to ischemia 173; 174. However, several clinical trials regarding 
these growth factors did not show satisfactory outcome as mentioned above 26; 40; 53. 
Therefore, the discovery of new factors and development of innovative therapies for 
improving cardiac angiogenesis and function are required. 
 
As a newly identified member of the HSP70 family, HSPA12B has been reported 
to regulate endothelial cell migration and tube formation during angiogenesis 113. 
Knockdown of HSPA12B could disrupt zebrafish vascular development and endothelial 
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cell angiogenesis 113; 114. In this chapter, we investigated whether HSPA12B is involved 
in regulating cardiac function and remodeling after MI.  
 
Materials and Methods 
 
Experimental Animals 
Endothelial Hspa12b knockout (eHspa12b-/-) mice were generated by cross-
breeding the conditionally targeted Hspa12b mice with C57BL/6.Cg-Tg (Tek-cre) mice 
which carry Cre recombinase under the control of the Tek promoter as described in our 
recent study 91. Wild type (WT) C57BL/6 mice were purchased from Jackson Laboratory 
(Indianapolis, IN). eHspa12b-/- and WT mice were maintained and bred at the Division of 
Laboratory Animal Resources at East Tennessee State University (ETSU). All mouse 
experimental procedures were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the National Institutes of Health (NIH 
Publication, 8th Edition, 2011) and approved by ETSU Committee on Animal Care. 
 
Induction of Myocardial Infarction 
Myocardial infarction was induced as previously described 82; 115. Briefly, mice 
(28-30g) were anaesthetized by 5.0% isoflurane (Henry Schein Animal Health, Ohio, 
USA), intubated, and ventilated with room air using a rodent ventilator (Hugo Sachs 
Elektronik, March, Germany). Anesthesia was maintained by inhalation of 1.5-2% 
isoflurane driven by 100% oxygen flow. Body temperature was regulated at 37˚C by 
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heating pad. Following the skin incision, the hearts were exposed through a left 
thoracotomy in the fourth intercostal space. The left anterior descending (LAD) coronary 
artery was permanently ligated with an 8-0 silk ligature. The skin was closed, 
anesthesia was discontinued, and the animals were allowed to recover in pre-warmed 
cages. In the sham surgery group, the ligature around mouse LAD coronary artery was 
not ligated and all the other procedures were the same as the MI group.  
 
Echocardiography 
To measure cardiac function, echocardiography was performed on anesthetized 
eHspa12b-/- and WT mice 28 days after MI or sham surgery with Toshiba Medical Aplio 
80 Imaging System (Tochigi, Japan) as described in our previous study 82; 175. 
Transthoracic two-dimensional M-mode Doppler spectral tracings were used to 
measure left ventricular (LV) wall thickness, LV end-diastolic diameter, and LV end-
systolic diameter. Percent ejection fraction (EF%) and fractional shortening (FS%) were 
calculated as previously described 175; 176. 
 
Masson's Trichrome Staining 
Twenty-eight days after MI, hearts from eHspa12b-/- and WT mice were 
harvested and cut horizontally. One slice below the ligation site was immersion-fixed in 
4% buffered paraformaldehyde, embedded in paraffin and cut at a 5 mm thickness. 
Paraffin slides were deparaffinized with Xylene for 3 times followed by hydration through 
100% ethanol, 95% ethanol, 85% ethanol, 70% ethanol to tap water. The sections were 
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then stained with trichrome stain (Masson) kit (Sigma-Aldrich, Missouri, USA) according 
to the manufacturer’s protocol 177. Lastly, slides were dehydrated in 95% and 100% 
alcohols, cleared in Xylene and followed by mounting with synthetic resin (Vector 
Laboratories, California, USA). The stained-sections were examined using EVOS 
Microscope (Thermo Fisher Scientific, Massachusetts, USA) and measured using 
Image J software (Version 1.389, NIH). 
 
Immunofluorescent staining 
Paraffin-embedded heart tissue sections were deparaffinized and rehydrated as 
described above. The sections were then placed in preheated antigen retrieval buffer, 
citrate buffer (pH 6.0, Sigma-Aldrich, Missouri, USA), at sub-boiling temperature for 10 
minutes followed by cooling down for 30 minutes. After washing with distilled water for 3 
times, the slides were blocked in 10% bovine serum albumin (BSA) (Thermo Fisher 
Scientific, Massachusetts, USA). Subsequently, the slides were incubated with primary 
antibody, specific anti-CD31 antibody (1:50 dilution, Abcam, ab28364), at 4°C overnight. 
The next day, sections were washed with Tris Buffered Saline buffer with 0.1% Tween 
20 (TBS/T) for 3 times, stained with the corresponding immunofluorescent secondary 
antibody (Thermo Fisher Scientific, Massachusetts, USA) at room temperature for 90 
minutes, and mounted using mounting media with 4′,6-diamidino-2-phenylindole (DAPI) 




The stained sections were examined using Confocal Microscope (Leica Camera, 
Wetzlar, Germany) and measured using Image J software (version 1.389, NIH). 
 
Protein Isolation and Western Blot 
Western blot was performed as described previously 82; 175. Briefly, tissue or 
cellular cytosolic and nuclear proteins were extracted from ischemic hearts or cells 
using Nuclear Extraction kit (Abcam, Cambridge, United Kingdom). Resuspend tissue or 
cell pellet in 1X Pre-extraction Buffer and incubate on ice for 10 minutes. Lysate was 
then vortexed vigorously for 10 seconds and centrifuged at 12,000 rpm for 1 minute. 
The cytoplasmic supernatant was transferred to a new tube and Nuclear Extraction 
Buffer was added to incubate on ice with vortex occasionally. After incubation for up to 1 
hour, lysate was centrifuged at 14,000 rpm for 10 minutes. The nuclear supernatant was 
transferred to a new tube.  
 
Protein concentration was determined by BCA protein assay kit (Thermo Fisher 
Scientific, Massachusetts, USA). Fifty µL Albumin Standard solution was diluted in 
distilled water, adjusting the concentration to 0, 2.5, 5, 7.5 and 10 μg/mL, and added to 
96-well plate. Cytoplasmic and nuclear proteins were also diluted in distilled water (2 µL 
protein solution + 8 µL water). Working reagent was prepared according to the 
manufacturer’s manual and added to each well (200 µL/well). Incubate the 96-well plate 
at 37°C for 30 minutes and read absorbance at 562 nm using Spectramax 340 
microplate reader. Protein concentrations were measured by SoftMax Pro 5.4.6. Adjust 
45 
 
the concentration of all proteins to the same level and add 4X sodium dodecyl sulfate 
(SDS) sample buffer (Thermo Fisher Scientific, Massachusetts, USA) followed by 
denaturing the proteins using dry baths heater (Fisher Scientific, Massachusetts, USA) 
at 99°C for 5 minutes. 
The tissue proteins were separated by SDS–polyacrylamide gel electrophoresis 
and transferred onto Hybond ECL membranes (Amersham Pharmacia, New Jersey, 
USA). The SDS-gel was prepared as shown in Table 1. The ECL membranes were 
blocked with 5% nonfat dry milk for 1 hour, incubated with the appropriate primary 
antibodies respectively at 4°C overnight, followed by incubation with peroxidase-
conjugated secondary antibodies (Cell Signaling Technology, 7074s and 7076s) at 
room temperature for 90 minutes and analysis by the ECL system (Amersham 
Pharmacia, New Jersey, USA). The following primary antibodies were used in this 
Chapter: anti-Angiopoietin1 (1:200 dilution, Santa Cruz Biotechnology, sc-6320); anti-
VEGF (1:1000 dilution, Abcam, ab46154); anti-VEGFR2 (1:1000 dilution, Cell Signaling 
Technology, 2479s); anti-GAPDH (1:1000 dilution, Cell Signaling Technology, 2118s). 
Anti-GAPDH was used as the housekeeping antibodies for heart tissue protein. The 
signals were analyzed and quantified using the G:Box gel imaging system (Syngene, 
Maryland, USA). 
 
Table 1. Preparation of 1 SDS-gel 




ddH2O 3.0 mL 1.5 mL 
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1.5 Tris-HCl, pH 8.8 1.9 mL -- 
1.5 Tris-HCl, pH 6.8 -- 625 µL 
Protogel solution 2.6 mL 325 µL 
10% SDS 77 µL 25 µL 
10% Ammonium persulfate (APS) 77 µL 19 µL 
Tetramethylethylenediamine (TEMED) 7.7 µL 2.5 µL 
Total volume 7.5 mL 2.5 mL 
 
Statistics 
Data are expressed as means ± SD. Comparisons of data between groups were 
made using 2 tailed t-test or one-way analysis of variance (ANOVA) followed by Tukey’s 




Endothelial Specific Deficiency of Hspa12b Exacerbates Cardiac Dysfunction and 
Increases Fibrosis after MI 
Previous research has reported that transgenic mice with endothelial cell specific 
overexpression of Hspa12b exhibit improved cardiac function following MI 115. In this 
study, we investigated the effect of endothelial cell HSPA12B on cardiac remodeling 
after MI using endothelial Hspa12b knockout (eHspa12b-/-) mice. Cardiac functions in 
wild type (WT) and eHspa12b-/- mice were examined by echocardiography 28 days after 
MI surgery. Figure 2A and B showed that MI significantly decreased cardiac function in 
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both WT and eHspa12b-/- mice. However, the values for ejection fraction (EF%) (36.7% 
± 2.36) and fractional shortening (FS%) (17.1% ± 1.20) in eHspa12b-/- MI mice were 
markedly lower than those in WT MI mice (46.6% ± 5.67 and 22.7% ± 3.40). In addition, 
fibrosis in the myocardium of eHspa12b-/- MI mice was significantly greater than that in 
WT MI hearts (Figure 2C). These data indicate that endothelial cell HSPA12B 
attenuates cardiac dysfunction and cardiac fibrosis in response to MI. 
Figure 2. Endothelial Hspa12b deficiency worsens cardiac dysfunction and 
increases fibrosis following myocardial infarction (MI). Wild type (WT) and 
endothelial cell specific Hspa12b knockout (eHspa12b-/-) mice were subjected to MI or 
sham surgical operation. Cardiac function was examined by echocardiography 28 days 
after surgery among WT sham (n=8), WT MI (n=8), eHspa12b-/- sham (n=5) and 
eHspa12b-/- MI (n=12) groups. A, Ejection fraction (EF%). B, Fractional shortening 
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(%FS). C, Cardiac fibrosis was examined by staining of heart tissue sections with 
Trichrome stain (Masson) kit. n=6/group. Comparisons of data between groups were 
made using one-way ANOVA followed by Tukey’s procedure or 2 tailed t-test. ** P <0.01, 
*** P <0.001 compared with indicated groups. 
 
Endothelial Specific Deficiency of Hspa12b Impairs Angiogenesis after MI 
Angiogenesis is an essential reparative event after MI, which increases perfusion 
of the ischemic myocardium and subsequently improves cardiac function 26; 40; 178. We 
examined whether endothelial cell deficiency of Hspa12b would impinge on cardiac 
angiogenesis after MI. Cardiac angiogenesis was evaluated by immunofluorescent 
staining of endothelial cell angiogenesis marker, cluster of differentiation 31 (CD31), in 
the myocardium four weeks after MI. As shown in Figure 3, there was more positive 
immunofluorescent staining of CD31 in WT MI myocardium compared with WT sham 
controls. However, the CD31 positive immunofluorescent staining in eHspa12b-/- MI 
hearts was markedly reduced by 54.4%, when compared with WT MI hearts. The data 




Figure 3. Endothelial Hspa12b knockout impairs angiogenesis after MI. WT and 
endothelial cell specific Hspa12b knockout (eHspa12b-/-) mice were subjected to MI or 
sham surgical operation. Cardiac angiogenesis was examined by immunostaining of 
heart tissue sections with specific anti-CD31 antibody (n=6-7), scale bar: 100µm. ** P 
<0.01, *** P <0.001 compared with indicated groups. 
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Endothelial Specific Deficiency of Hspa12b Attenuates MI Induced Angiogenetic Factor 
Expression 
Angiopoietin-1 (Ang1), vascular endothelial growth factor (VEGF), and VEGFR2 
are important angiogenetic factors for the induction of angiogenesis 34; 179; 180. Ang1 was 
reported to stabilize blood vessels, reduce endothelial cell permeability as well as 
improve cardiac dysfunction following MI 45; 47; 180; 181. Moreover, VEGF plays an 
essential role in new blood vessel formation in mouse myocardium and liver 179. As a 
receptor for VEGF, VEGFR2 activation is responsible for the induction of angiogenesis 
in cardiac endothelial cells 182. We isolated protein from heart tissues and investigated 
whether knockout of Hspa12b will affect angiogenetic factor expression after MI. Figure 
4 showed that MI significantly upregulated Ang1, VEGF and VEGFR2 expression. 
However, the levels of Ang1, VEGF and VEGFR2 in the eHspa12b-/- MI hearts were 
significantly lower than those in WT MI myocardium, indicating that HSPA12B is 
essential for angiogenetic factor expression after MI. 
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Figure 4. Endothelial Hspa12b deficiency attenuates MI-induced angiogenetic 
factor expression. WT and endothelial cell specific Hspa12b knockout (eHspa12b-/-) 
mice were subjected to MI or sham surgical operation. The levels of angiogenetic 
markers Ang1 (n=5-6), VEGF (n=5-6), and VEGFR2 (n=4) in the myocardium were 
examined by Western blot. GAPDH was used as loading control. ** P <0.01, *** P <0.001 




In this study, in order to investigate whether HSPA12B affect cardiac function 
and remodeling after MI, we generated a transgenic mouse with endothelial cell specific 
Hspa12b deficiency. We discovered that mice with specific deficiency of endothelial 
HSPA12B were characterized by poorer prognosis after MI, worsened cardiac function, 
less angiogenesis and increased cardiac fibrosis, as compared with wild type MI mice. 
This led us to investigate the biological function of HSPA12B in the process of cardiac 
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regeneration following MI. Angiogenesis is a sophisticated multistep process that plays 
an essential role in the improvement of MI. Several proangiogenic factors, including 
Ang1 and VEGF, regulate myocardial angiogenesis 34; 180; 183. Ma et al has reported that 
overexpression of HSPA12B increased Ang1 and VEGF expression in lung cancer, 
facilitating lung tumorigenesis 184. In accordance, our data show that specific knockout 
of endothelial Hspa12b can attenuate MI induced expression of Ang1, VEGF and 
VEGFR2 in vivo. Therefore, endothelial HSPA12B plays an important role in 
maintaining cardiac function and angiogenesis post-MI.  
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CHAPTER 3. HSPA12B IS REQUIRED FOR ENDOTHELIAL CELL PROLIFERATION, 




Endothelial cells are one of the most abundant cell types in the heart that support 
cardiac contractile function, and participate in myocardial angiogenesis after cardiac 
injury 26; 58. Endothelial cells switch from a quiescent to an activated state when exposed 
to proangiogenic signals, which lead to the upregulation of cell migrative and 
proliferative rate 71. Elevated migration and proliferation of endothelial cells triggers the 
formation and maturation of the neovessels. Insufficient angiogenic switch of endothelial 
cells following cardiac ischemic injury will lead to endothelial cell dysfunction and 
decreased revascularization, thereby impairing cardiac angiogenesis 53. Hence, it is of 
great importance to investigate the growth and activation of endothelial cells under 
hypoxic conditions. The results from Chapter 2 indicate that endothelial cell HSPA12B is 
required for cardiac angiogenesis and maintaining cardiac function after MI. In order to 
study whether HSPA12B plays a role in endothelial cell proliferation, migration and 
angiogenesis, we used adenoviral HSPA12B to induce the expression of HSPA12B in 





Materials and Methods 
 
Cells and Cell Culture 
Human umbilical vein endothelial cell (HUVEC) cell line was purchased from 
American Type Culture Collection (ATCC, Virginia, USA). HUVECs were cultured in 
Gibco™ Ham's F-12K (Kaighn's) Medium (Thermo Fisher Scientific, Massachusetts, 
USA) supplemented with growth factors and 5% Fetal Bovine Serum (FBS) (Atlanta 
Biologicals, Georgia, USA). Before seeding cells, 1.5% gelatin from porcine skin 
(Sigma-Aldrich, Missouri, USA) was used to coat cell culture plate.  
 
Endothelial Cell Transfection and Treatments 
When HUVECs reached 70-80% confluence, the culture media was replaced 
with half volume serum-free media and cells were transfected with siRNA (Invitrogen by 
Life Technologies, California, USA) specific for HSPA12B. Scrambled siRNAs served as 
controls. Generally, the siRNA transfection agent siPORT™ NeoFX™ Transfection 
Agent (Invitrogen by Life Technologies, California, USA) was diluted in opti-MEM 
(Thermo Fisher Scientific, Massachusetts, USA) and incubated for 10 minutes at room 
temperature. At the same time, the siRNA was also diluted in opti-MEM. Then the 
siRNA and transfection agent were mixed and incubated for another 10 minutes at room 
temperature and dispensed into wells. Six hours later, half volume normal growth 
medium was added. In separate experiments, HUVECs were transfected with 
adenovirus expressing HSPA12B labelled with green fluorescence protein (GFP) (Ad-
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HSPA12B, MOI=10). Adenovirus expressing scrambled GFP served as control. Twenty-
four hours after transfection with either siRNA or adenovirus, the HUVECs were 
incubated at 37°C with 5% CO2 and 0.1% O2 in a hypoxia chamber (Pro-Ox Model C21, 
BioSpherix Ltd., Redfield New York, USA) for additional 24 hours as described 
previously 185. The cells that were not subjected to hypoxia were incubated at 37°C with 
5% CO2 in a CO2 incubator (Thermo Fisher Scientific, Massachusetts, USA) and served 
as controls (normoxia).  
 
Endothelial Cell Proliferation Assay 
The HUVEC proliferative activity was measured by 5-ethynyl-2-deoxyuridine 
(EdU) incorporation assay and MTT assay.  
 
EdU Incorporation Assay. Click-iT Edu imaging kit (Invitrogen by Life 
Technologies, California, USA) was used to perform EdU incorporation assay. HUVECs 
were seeded in 24-well plates. After treatments, dilute EdU stock solution in cell culture 
medium (20 μM). Remove half volume of medium from endothelial cells and add same 
volume of EdU labeled solution, making the final concentration 20 μM. Cells were 
incubated in a hypoxia chamber or normal incubator. Four hours later, endothelial cells 
were fixed and permeabilized as mentioned above, and followed by washing twice using 
3% BSA in PBS. At the same time, Click-iT® reaction cocktail was prepared according 
to the manufacturer’s protocol. Remove wash buffer, add Click-iT® reaction cocktail to 
each well and incubate for 30 minutes at room temperature (protecting from light). After 
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incubating, endothelial cells were washed twice with 3% BSA in PBS, once with PBS 
and stained with 1X Hoechst® 33342 solution for additional 30 minutes at room 
temperature. The proliferation rate of EdU incorporation was calculated by normalizing 
the number of EdU positive cells to the 1X Hoechst® 33342-stained cells. EdU staining 
images were taken using EVOS Microscope and measured using Image J software 
(Version 1.389, NIH). 
 
MTT Assay. MTT cell proliferation assay kit (Thermo Fisher Scientific, 
Massachusetts, USA) was used to perform MTT assay. HUVECs were seeded in 96-
well plates. After treatments, endothelial cells were labeled with MTT by adding MTT 
stock solution to each well in terms of the manufacturer’s protocol. Cells were incubated 
at 37°C for 4 hours followed by removing all but 25 µL of medium from each well and 
adding 50 µL dimethyl sulfoxide (DMSO) to each well. Each sample was mixed 
thoroughly and incubated at 37°C for 10 minutes. The medium in each well was mixed 
again and read absorbance at 540 nm using a Microplate Spectrophotometer 
(Spectramax 340, California, USA).  
 
Endothelial Cell Migration Assay 
Endothelial cell migration capacity was measured by the scratch (or wound-
healing) assay 186 when cells reached 80% confluence. HUVECs were seeded in 12-
well plates and scratched with 200 µl tips 24 hours after siRNA or adenoviral 
transfection. Scratched endothelial cells floated in the medium was gotten rid of by 
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changing medium. Cells were incubated with empty F-12K medium without growth 
factor after scratching and subjected to hypoxic or normoxic challenge. Mitomycin C (5 
μg/ml, Invitrogen by Life Technologies, California, USA) was used to inhibit cell 
proliferation one hour prior to scratch. Bright field images were taken 24 hours after 
injury using EVOS Microscope. The percent closure of the wound was analyzed by an 
image analyzer (Image J, NIH). 
 
Matrigel-Based In Vitro Angiogenesis Assay 
Endothelial cell angiogenesis was assessed using Matrigel based angiogenesis 
assay 113. Briefly, processed HUVECs were trypsinized, washed and seeded on 
Matrigel-coated 96-well plates (Corning, New York, USA) with 104 cells/well and 
photographed six hours after incubating at 37°C with 5% CO2. Total number of master 
junction was quantified by ImageJ, NIH. 
 
Protein Isolation and Western Blot 
Western blot was performed as described in Chapter 2. The primary antibodies 
used in this Chapter were: anti-Angiopoietin1 (1:200 dilution, Santa Cruz Biotechnology, 
sc-6320); anti-VEGF (1:1000 dilution, Abcam, ab46154); anti-VEGFR2 (1:1000 dilution, 
Cell Signaling Technology, 2479s); anti-GAPDH (1:1000 dilution, Cell Signaling 
Technology, 2118s). Anti-GAPDH was used as the housekeeping antibodies for 
endothelial cell protein. 
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Quantitative Real-time PCR (qRT-PCR) 
Total RNA was isolated from cultured cells using RNAzol®RT (Molecular 
Research Center, Ohio, USA) in accordance with the manufacture’s protocol as 
described previously 139. In brief, after homogenization of endothelial cells with 
RNAzol®RT, add Diethyl pyrocarbonate (DEPC) water, mix gently and incubate at room 
temperature for 5 – 10 minutes followed by centrifuging at 12,000g for 15 minutes. The 
supernatant was transferred to a new tube and 75% ethanol was added. Wait another 
10 minutes and centrifuge at 12,000g for 8 minutes. Remove the supernatant, wash the 
mRNA fraction with 75% ethanol twice and dissolve the mRNA in DEPC water. The 
concentration of RNA was tested using Nano Drop Spectrophotometer (NanoDrop 
Technologies, Delaware, USA). 
 
mRNA was converted to cDNA by High Capacity cDNA Transcription kit (Applied 
Biosystems, California, USA). The reverse transcription master mix was prepared as 
shown in Table 2. Both cDNA reverse transcription and quantitative real-rime PCR 
(qRT-PCR) were conducted using a 4800 RT-PCR machine (Bio-Rad, California, USA). 
qRT-PCR was performed using specific Taqman primers (Applied Biosystems, 
California, USA) and Taqman Universal Master Mix (Applied Biosystems, California, 
USA) (Table 3). The mRNA levels of VEGF and Ang1 were quantified with the 2 (-ΔΔct) 





Table 2. Preparation of the 2X Reverse Transcription (RT) Master Mix 
Component Volume 
10X RT Buffer 2.0 µL 
25X dNTP Mix (100 mM) 0.8 µL 
10X RT Random Primers 2.0 µL 
MultiScribeTM Reverse Transcriptase 1.0 µL 
Nuclease-free H2O 4.2 µL 
Total per Reaction 10 µL 
 
Table 3. Preparation of the qRT-PCR Master Mix 
Reagent Volume per single 20 µL reaction 
2X Taqman Universal Master Mix 10 µL 
Taqman primers 1 µL 
Nuclease-free H2O 7 µL 
cDNA 2 µL 
 
Statistics 
Data are expressed as means ± SD. Comparisons of data between groups were 
made using 2 tailed t-test or one-way analysis of variance (ANOVA) followed by Tukey’s 






Transfection of Adenoviral HSPA12B Promotes HSPA12B Expression in Endothelial 
Cells 
To further validate the pro-angiogenic role of HSPA12B in endothelial cells, 
human umbilical vein endothelial cells (HUVECs) were transfected with adenoviral 
HSPA12B (Ad-HSPA12B) or Ad-GFP before hypoxia in vitro. Figure 5A and B shows 
that almost all endothelial cells were transfected with adenovirus and transfection with 
Ad-HSPA12B significantly induced the expression of HSPA12B in endothelial cells.  
 
Figure 5. Transfection of adenoviral HSPA12B increases the expression of 
HSPA12B in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were 
transfected with adenovirus expressing HSPA12B labelled with green fluorescence 
protein (GFP) (Ad-HSPA12B, MOI=10). Immunofluorescent staining (A) and western 
blotting (B) were performed to show that Ad-HSPA12B transfection promotes HSPA12B 




HSPA12B Promotes Endothelial Cell Proliferation Following Hypoxic Challenge 
During the formation of blood vessels, endothelial cells switch from the quiescent 
stage to a growth period 187. In the present study, endothelial cell proliferation was 
measured by EdU incorporation assay and MTT assay. As shown in Figure 6A, there 
are more EdU incorporation in hypoxia group when compared with the normoxia 
treatment, suggesting that hypoxia alone markedly increased endothelial cell 
proliferation. In addition, MTT also shows that endothelial cell proliferation rate is 
upregulated in response to hypoxic challenge (Figure 6B). Moreover, increased 
expression of HSPA12B by transfection of Ad-HSPA12B profoundly promoted hypoxia-
induced cell proliferation by 24.6% in EdU incorporation and 15.2% in MTT assay, when 
compared with respective hypoxic controls (Figure 6A and B). 
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Figure 6. HSPA12B promotes endothelial cell proliferation following hypoxic 
challenge. HUVECs were transfected with adenovirus expressing HSPA12B (Ad-
HSPA12B) or Ad-GFP. Twenty-four hours after transfection, cells were subjected to 
hypoxia or normoxia. Cell proliferation was examined by Edu incorporation (A) and MTT 





HSPA12B Induces Endothelial Cell Migration Following Hypoxia 
Endothelial cell migration is a critical process during the activation of endothelial 
angiogenesis 26. Therefore, we continued to investigate whether HSPA12B regulates 
endothelial cell migration by wound-healing assay. Compared with the control group, 
hypoxia promotes endothelial cell migration dramatically as evidenced by increased 
percentage of recovered area after hypoxia (Figure 7). Increased expression of 
HSPA12B further increased hypoxia-induced endothelial cell migration by 36.7%, when 
compared with hypoxic control (Figure 7), indicating the positive role of HSPA12B in 
cell migration. 
Figure 7. HSPA12B induces endothelial cell migration following hypoxic 
challenge. HUVECs were transfected with adenovirus expressing HSPA12B (Ad-
HSPA12B) or Ad-GFP. Twenty-four hours after transfection, cells were subjected to 
hypoxia or normoxia. Cell migration was examined by wound-healing assay, scale bars: 
400µm. n=3 independent experiments/group. * P< 0.05, ** P< 0.01, *** P< 0.001 
compared with indicated group. 
64 
 
HSPA12B Enhances Endothelial Cell Angiogenesis and Angiogenetic Factor 
Expression after Hypoxia 
We next performed Matrigel-based tube formation assay to examine whether 
HSPA12B influences endothelial angiogenesis after hypoxic challenge. Figure 8 
showed that transfection of HUVECs with Ad-HSPA12B significantly increased both 
normoxia and hypoxia-induced master junction numbers, indicating that HSPA12B 
positively regulates endothelial cell angiogenesis. 
Figure 8. HSPA12B promotes endothelial cell angiogenesis following hypoxic 
challenge. HUVECs were transfected with adenovirus expressing HSPA12B (Ad-
HSPA12B) or Ad-GFP. Twenty-four hours after transfection, cells were subjected to 
hypoxia or normoxia. Angiogenesis was examined by Matrigel assay, scale bars: 
400µm. n=3 independent experiments/group. * P< 0.05, ** P< 0.01, *** P< 0.001 




Angiogenetic factors have been reported to play a critical role in the regulation of 
endothelial cell proliferation and angiogenesis 188; 189. Therefore, we examined the effect 
of HSPA12B on the expression of angiogenetic factors including Ang1, VEGF and 
VEGFR1 following hypoxic challenge. Figure 9A showed that hypoxic challenge alone 
upregulated expression of Ang1, VEGF and VEGFR2 in HUVECs. Importantly, 
transfection of HUVECs with Ad-HSPA12B further increased the levels of Ang1, VEGF 
and VEGFR2, when compared with hypoxia control. In addition, transfection of HUVECs 
with Ad-HSPA12B markedly increased the mRNA levels of Ang1 and VEGF (Figure 9B 
and C). These data further confirmed the role of HSPA12B in promoting endothelial cell 
proliferation and angiogenesis. 
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Figure 9. HSPA12B upregulates endothelial cell angiogenetic factor expression 
after hypoxia. HUVECs were transfected with adenovirus expressing HSPA12B (Ad-
HSPA12B) or Ad-GFP. Twenty-four hours after transfection, cells were subjected to 
hypoxia or normoxia. The levels of angiogenetic markers (Ang1, VEGFand VEGFR2) 
were examined by Western blot (A) and qRT-PCR (B-C). GAPDH was used as loading 
control for Western blot. β-Actin was used as loading control for qRT-PCR. n=3 





Silence of HSPA12B Attenuates Endothelial Cell Proliferation Following Hypoxia 
In contrast, we transfected HUVECs with siRNA for HSPA12B to knockdown the 
expression of HSPA12B in endothelial cells before cells were subjected to hypoxia. 
Scrambled siRNA (siNC) was used as a control. EdU staining and MTT assay were 
performed to examine cell proliferation. We observed that suppression of HSPA12B 
expression by transfection of HUVECs with siRNA for HSPA12B markedly suppressed 
hypoxia induced EdU incorporation, suggesting decreased cell proliferative rate after 
transfection with siRNA for HSPA12B (Figure 10A). MTT assay also revealed that 




Figure 10. siRNA silencing of HSPA12B or YAP attenuates hypoxia induced 
endothelial cell proliferation. HUVECs were transfected with siRNA specific for 
HSPA12B (siHSPA12B) or for YAP (siYAP). Scrambled siRNA served as control (siNC). 
Twenty-four hours after transfection, the endothelial cells were subjected to hypoxia or 
normoxia. Cell proliferation was measured by Edu incorporation (n=3, A) and MTT 





Silencing of HSPA12B Inhibits Hypoxia Induced Endothelial Cell Migration 
In addition, Figure 11 showed that the percentage of recovered area after 
scratch were lower in cells transfected with siRNA for HSPA12B following hypoxia than 
in hypoxia control group. The data demonstrates that HSPA12B plays an important role 
in promoting endothelial cell migration. 
Figure 11. siRNA silencing of HSPA12B or YAP suppresses hypoxia induced 
endothelial cell migration. HUVECs were transfected with siRNA specific for 
HSPA12B (siHSPA12B) or for YAP (siYAP). Scrambled siRNA served as control (siNC). 
Twenty-four hours after transfection, the endothelial cells were subjected to hypoxia or 
normoxia. Cell migration was examined by wound-healing assay, scale bars: 1000µm. 





Silencing of HSPA12B Attenuates Hypoxia Induced Endothelial Cell Angiogenetic 
Factor Expression 
We then confirmed that HSPA12B is required for hypoxia-induced expression of 
angiogenetic factors by siRNA-mediated silence of HSPA12B. Indeed, silencing of 
HSPA12B markedly suppressed hypoxia-induced the expression of angiogenetic factor 
Ang1, VEGF and VEGFR2 (Figure 12), suggesting that HSPA12B is involved in the 
regulation of angiogenetic factor expression which regulates endothelial cell 
proliferation, migration, and angiogenesis. Collectively, the data demonstrates that 
HSPA12B plays an important role in promoting angiogenesis.   
Figure 12. siRNA silencing of HSPA12B or YAP decreases hypoxia induced 
angiogenetic factor expression. HUVECs were transfected with siRNA specific for 
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HSPA12B (siHSPA12B) or for YAP (siYAP). Scrambled siRNA served as control (siNC). 
Twenty-four hours after transfection, the endothelial cells were subjected to hypoxia or 
normoxia. The levels of Ang1 (n=3), VEGF (n=4) and VEGFR2 (n=3) were examined by 
Western blot. GAPDH was used as loading control. * P< 0.05, ** P< 0.01, *** P< 0.001 




As mentioned above, in most conditions, endothelial cells are in a quiescent 
state. When exposed to pathological stimulation such as hypoxia, ischemia and other 
injuries, endothelial cells begin to form new blood vessels in order to maintain cellular 
homeostasis 71; 190. Given that endothelial cell proliferation and migration play a critical 
role in angiogenesis, we performed EdU staining, MTT assay and wound healing assay, 
respectively. Our results indicate that overexpression of HSPA12B further upregulated 
hypoxia induced proliferation and migration. In contrast, knockdown of HSPA12B 
significantly depleted cell proliferation and migration induced by hypoxia. Importantly, 
overexpression of HSPA12B increased hypoxia stimulated tube formation and 
angiogenetic factor expression including Ang1, VEGF and VEGFR2, while knockdown 
of HSPA12B strongly attenuated the levels of Ang1, VEGF and VEGFR2 in HUVECs 
induced by hypoxic challenge. Our results indicate the requirement of HSPA12B in 




CHAPTER 4. ENDOTHELIAL CELL YAP INDUCES ANGIOGENESIS AND IMPROVES 




As an important component in the highly conserved Hippo/YAP signaling 
pathway, YAP plays a critical role in cardiac remodeling after various cardiovascular 
diseases 127; 191; 192. Lin et al reported that activation of cardiac specific YAP using AAV9 
attenuated cardiac dysfunction induced by MI 131. Conversely, cardiac specific knockout 
of Yap resulted in increased cardiac apoptosis and fibrosis following MI or pressure 
overload induced cardiac hypertrophy 142; 193. Importantly, suppression of epicardial Yap 
prohibited epicardial-to-mesenchymal transition and impaired vasculature development 
in the heart 194. A recent study by Neto and colleagues showed that endothelial YAP 
plays an important role in regulating endothelial cell stability and adherens junction 
morphology 195. Inhibition of YAP blocked mechanical stress stimulated endothelial cell 
proliferation, migration and blood vessel formation, indicating the critical role of 
endothelial cell YAP in angiogenesis in vitro. However, whether endothelial cell YAP is 
involved in cardiac angiogenesis following cardiac ischemic injury remains unclear. In 
this study, we developed endothelial cell specific deficient mouse to examine the 




Materials and Methods 
 
Generation of Endothelial Specific Yap Knockout Mice 
Endothelial specific Yap knockout (eYap-/-) mice were generated by 
crossbreeding of Yapflox/flox mice (a gift from Dr. Eric Olson, University of Texas 
Southwestern Medical Center, Dallas) with Tek-Cre mice (Jackson Laboratory, 008863). 
Genotypes for the endothelial cell specific deletion of Yap were confirmed by PCR 
analysis of floxed allele (YAP LA F: ACA TGT AGG TCT GCA TGC CAG AGG AGG; 
YAP EX R: AGG CTG AGA CAG GAG GAT CTC TGT GAG. 600 bp for LoxP allele and 
457 bp for wild type allele), YAP deletion (YAP LA F: ACA TGT AGG TCT GCA TGC 
CAG AGG AGG; YAP SA R: TGG TTG AGA CAG CGT GCA CTA TGG AGC. 338 bp 
product for deletion). Cre gene expression was also examined by PCR. In addition, 
immunofluorescent staining was performed to identify endothelial cell specific deficiency 
of Yap. 
 
Myocardial Infarction and Echocardiography 
Both eYap-/- and WT mice were subjected to MI or sham surgery, and 
echocardiography was performed 28 days after surgery as described in Chapter 2. EF% 





Hearts from eYap-/- and WT mice were harvested and cut horizontally. Then 
slices were immersion-fixed in 4% buffered paraformaldehyde, embedded in paraffin 
and cut at a 5 mm thickness. Immunofluorescent staining of paraffin-embedded heart 
tissue sections was performed as described above in Chapter 2. The primary antibodies 
used in this Chapter were: anti-CD31 antibody (1:50 dilution, Abcam, ab28364) and 
anti-YAP antibody (1:100 dilution, Cell Signaling Technology, 4912s). The stained 
sections were examined using Confocal Microscope (Leica Camera, Wetzlar, Germany) 
and measured using Image J software (version 1.389, NIH). 
 
Endothelial Cell Transfection and Treatments 
HUVECs were transfected with siRNA (Invitrogen by Life Technologies, 
California, USA) specific for YAP as described in Chapter 3. Scrambled siRNAs were 
served as controls. Twenty-four hours after transfection with siRNA, the cells were 
subjected to hypoxia or normoxia for another 24 hours. In separate experiments, YAP 
inhibitor verteporfin (VP, 1 mmol/L, Millipore Sigma, Missouri, USA) or vehicle control 





Endothelial Cell Proliferation Assay, Migration Assay and Matrigel-Based In Vitro 
Angiogenesis Assay 
As mentioned in Chapter 3, the HUVEC proliferative activity was measured by 
EdU incorporation assay and MTT assay; endothelial cell migration capacity was 
measured by the wound-healing assay; and endothelial cell angiogenesis was assessed 
using Matrigel based angiogenesis assay. Images were taken using EVOS Microscope 
and measured using Image J software (Version 1.389, NIH). 
 
Western Blot 
Western blot was performed as described in Chapter 2. The primary antibodies 
used in this Chapter were: anti-Angiopoietin1 (1:200 dilution, Santa Cruz Biotechnology, 
sc-6320); anti-VEGF (1:1000 dilution, Abcam, ab46154); anti-VEGFR2 (1:1000 dilution, 
Cell Signaling Technology, 2479s); anti-GAPDH (1:1000 dilution, Cell Signaling 
Technology, 2118s); anti-β-actin (1:1000 dilution, Cell Signaling Technology, 3700s). 
Anti-GAPDH or anti-β-actin was used as the housekeeping antibodies for endothelial 
cell or heart tissue protein. 
 
qRT-PCR 
Total RNA was isolated from cultured cells and mRNA was converted to cDNA 
as mentioned in Chapter 3. The mRNA levels of VEGF and Ang1 were quantified with 
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the 2 (-ΔΔct) relative quantification method that were normalized to β-Actin (Applied 
Biosystems, California, USA). 
 
Statistics 
Data are expressed as means ± SD. Comparisons of data between groups were 
made using 2 tailed t-test or one-way analysis of variance (ANOVA) followed by Tukey’s 




Confirmation of Endothelial Specific Deficiency of Yap Mouse 
YAP has been reported to promote angiogenesis both in brain and during tumor 
growth 168; 169. In our study, endothelial specific Yap knockout mice were constructed by 
crossbreeding of Yapflox/flox mice and Tek-Cre mice. Endothelial cell Yap knockout was 
confirmed by immunofluorescent staining (Figure 13). The expression of YAP in heart 
tissue was revealed by red fluorescence and the endothelial cell marker was stained in 
green. As shown in Figure 13, there was co-localization of YAP and CD31 in WT heart 
tissue, indicating endothelial cell YAP is expressed in the heart tissue. However, no co-
localization of YAP and CD31 was detected in endothelial cell specific Yap deficient 
(eYap-/-) mice, showing that endothelial Yap has been specifically knocked out. 
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Figure 13. Immunofluorescent staining of YAP expression in heart tissue 
sections. The expression of YAP (red) and its co-localization with endothelial marker 
CD31 (green) in the heart tissue of WT and eYap-/- mice were tested by 
immunofluorescent staining. n=3/group. Scale bar: 50µm. 
 
Endothelial Specific Deficiency of Yap Impairs Cardiac Angiogenesis after MI 
To further validate whether YAP plays a critical role in the regulation of 
angiogenesis after MI, we induced MI in both eYap-/- and WT mice. First, we examined 
the effects of Yap knockout on cardiac angiogenesis after MI. Figure 14 showed that 
the positive immunofluorescent staining of CD31 were markedly decreased in the eYap-
/- MI hearts, when compared with WT MI hearts, indicating that YAP is required for 
endothelial angiogenesis in the myocardium.  
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Figure 14. Endothelial specific Yap deficiency (eYap-/-) exhibit impaired 
angiogenesis after MI. WT and eYap-/- mice were subjected to MI or sham surgical 
operation. A, Cardiac angiogenesis was examined by immunostaining of heart tissue 
sections with specific anti-CD31 antibody (n=6-8), scale bar: 50µm. *** P <0.001 
compared with indicated group. 
 
In addition, the levels of angiogenetic factors, such as Ang1, VEGF and VEGFR2 
in the myocardium of eYap-/- MI mice were significantly lower than those in WT MI 
hearts (Figure 15). Together, our data demonstrates that endothelial YAP plays an 
important role in the regulation of cardiac angiogenesis following MI challenge. 
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Figure 15. Endothelial Yap deficiency attenuates MI-induced angiogenetic factor 
expression. WT and eYap-/- mice were subjected to MI or sham surgical operation. The 
levels of angiogenetic factors Ang1, VEGF and VEGFR2 in the myocardium were 
examined by Western blot (n=4-5). GAPDH was used as loading control. * P< 0.05, ** 
P< 0.01, *** P< 0.001 compared with indicated group. 
 
Endothelial Specific Deficiency of Yap Worsens Cardiac Dysfunction after MI 
Angiogenesis is an essential reparative event after MI, which increases perfusion 
of the ischemic myocardium and subsequently improves cardiac function. Next, we 
examined cardiac function following MI. As expected, Yap deficiency led to worsened 
cardiac dysfunction after MI, as compared with WT MI mice (Figure 14A and B). 
Specifically, the values of EF% (38.0% ± 4.26) and FS% (17.9% ± 2.27) in eYap-/- MI 
mice were markedly lower than that in WT MI mice (46.0% ± 4.41; 22.3% ± 2.42). The 
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data showed that YAP takes a critical part in maintaining cardiac function following MI 
challenge.  
Figure 16. Endothelial specific Yap knockout (eYap-/-) mice exhibit an exacerbated 
cardiac dysfunction after MI. WT and eYap-/- mice were subjected to MI or sham 
surgical operation. A-B, Cardiac function was examined by echocardiography 28 days 
after surgery among WT sham (n=6), WT MI (n=7), eYap-/- sham (n=4) and eYAP-/- MI 
(n=7) groups. ** P <0.01, *** P <0.001 compared with indicated group. 
 
YAP Promotes Endothelial Cell proliferation, Migration and Angiogenesis Following 
Hypoxia 
We then examined the effect of YAP on hypoxia induced cell proliferation, 
migration and angiogenesis. HUVECs were transfected with siRNA for YAP before the 
cells were subjected to hypoxia. As shown in Figure 10A, silencing of YAP prevented 
hypoxia induced EdU incorporation of endothelial cells, indicating that YAP is required 
for endothelial cell proliferation after hypoxia. In addition, MTT assay also revealed that 
suppression of YAP attenuated endothelial cell proliferation promoted by hypoxic 
challenge (Figure 10B). We next performed wound-healing assay and observed that 
hypoxia promoted percentage of recovered area was significantly eliminated with 
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transfection of siRNA for YAP after hypoxia (Figure 11), suggesting that YAP plays an 
important role in endothelial cell migration. Moreover, silencing of YAP also suppressed 
hypoxia induced expression of angiogenetic factors including Ang1, VEGF and its 
receptor, VEGFR2, indicating the angiogenetic role of YAP in endothelial cells (Figure 
12). Together, these data show that YAP is required for accelerating endothelial cell 
proliferation and angiogenesis after hypoxia. 
 
Administration of Verteporfin Suppressed Endothelial Cell Proliferation, Migration and 
Angiogenesis Induced by Hypoxia 
Next, we inhibited YAP activity in endothelial cells by Verteporfin (VP) 
administration. One hour after treatment with VP, HUVECs were subjected to hypoxia. 
EdU incorporation assay showed that VP administration significantly reduced positive 
staining stimulated by hypoxic challenge (Figure 17A), suggesting the negative role of 
VP in endothelial cell proliferation. MTT assay also indicated that inhibition of YAP by 
VP attenuates hypoxia promoted endothelial cell proliferation (Figure 17B). 
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Figure 17. YAP inhibition suppresses hypoxia-induced endothelial cell 
proliferation. Endothelial cells were treated with YAP inhibitor, Verteporfin (VP, 1 mM) 
before the cells were subjected to hypoxic challenge. Endothelial cell proliferation was 
determined by Edu incorporation (A) and MTT assay (B), scale bars: 400µm. n=3-5 
independent experiments/group. * P< 0.05, ** P< 0.01, *** P< 0.001 compared with 
indicated group. 
 
Subsequently, we performed scratch assay (Figure 18) and found that 
deactivation of YAP by administration of VP in endothelial cells prohibited endothelial 
cell migration after hypoxic challenge, which is consistent with our above result using 
siRNA for YAP.   
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Figure 18. YAP inhibition suppresses hypoxia-induced endothelial cell migration. 
Endothelial cells were treated with YAP inhibitor, Verteporfin (VP, 1 mM/L) before the 
cells were subjected to hypoxic challenge. Cell migration was determined by wound-
healing assay, scale bars: 400µm. n=3 independent experiments/group. * P< 0.05, ** 
P< 0.01, *** P< 0.001 compared with indicated group. 
 
Matrigel-based in vitro angiogenesis assay further confirmed that treatment with 
VP decreased master junction numbers enhanced by hypoxia, suggesting that 
suppression of YAP attenuated hypoxia promoted angiogenesis (Figure 19A). In 
addition, qRT-PCR showed that hypoxia induced RNA levels of angiogenetic factor 
Ang1 and VEGF (Figure 19B and C) were significantly reversed by administration of 





Figure 19. YAP inhibition suppresses hypoxia-induced endothelial cell 
angiogenesis. Endothelial cells were treated with YAP inhibitor, Verteporfin (VP, 1 mM) 
before the cells were subjected to hypoxic challenge. Angiogenesis was examined by 
Matrigel assay, scale bars: 400µm. Expression of Ang1 and VEGF were examined by 
Western blot (A) and qRT-PCR (B-C). n=3 independent experiments/group. * P< 0.05, 




Several pieces of evidence have shown that YAP is involved in regulating cardiac 
myocyte proliferation and regeneration 127; 130; 131; 191; 192. Our group has investigated that 
85 
 
large tumor suppressor kinase1 (LATS1), an upstream regulator of YAP, participates in 
stress overload-induced cardiac fibroblast proliferation and differentiation previously 139. 
In the current study, we discovered that YAP expression was significantly upregulated in 
MI heart in vivo, accompanied with robust angiogenesis during the cardiac repair after 
MI. However, endothelial specific knockout of Yap worsened cardiac dysfunction 
following MI and impairs MI induced cardiac angiogenesis. Knockout of endothelial Yap 
also downregulated the expression of angiogenetic factors (Ang1, VEGF and VEGFR2) 
induced by cardiac ischemic injury in the myocardium.  
 
Indeed, several groups have reported the involvement of YAP in angiogenesis 
during development and tumorigenesis through enhanced secretion of proangiogenic 
factors and stabilization of endothelial junction 49; 50; 196; 197. To investigate the function of 
YAP in cardiac angiogenesis following MI, HUVECs were cultured under hypoxia 
condition. We observed that hypoxia stimulation promoted proliferation, migration and 
angiogenesis of endothelial cells in vitro. However, both siRNA-mediated knockdown of 
YAP and VP administration strongly decreased proliferation and impeded migration 
promoted by hypoxia in endothelial cells. Importantly, prevention of YAP nuclear 
localization by VP administration significantly disturbed angiogenesis and decreased 
Ang1 and VEGF expression of endothelial cells. Our results revealed that endothelial 





CHAPTER 5. ENDOTHELIAL CELL HSPA12B AND YAP COOPERATIVELY 




Recently, HSPA12B has been reported to promote angiogenesis by mediating 
the turnover of anti-angiogenic/pro-tight junction proteins such as AKAP12 184 in lung 
cancer and via activating PI3K/Akt signaling 116; 118 in endotoxin induced sepsis and 
cerebral I/R. Previous studies have shown that activation of eNOS also contributes to 
HSPA12B induced angiogenesis during the process of ischemic stroke 117. However, 
the detailed cellular and molecular mechanisms by which HSPA12B regulates 
angiogenesis following MI have not been elucidated. In addition, the mechanisms by 
which MI injury or hypoxia upregulates HSPA12B production remain unclear. Heat 
shock proteins (HSPs) are highly conserved molecular chaperons to facilitate protein 
maturation and signaling pathways 198; 199. Previous studies showed several HSPs, 
including HSP90 and HSP27, are involved in regulation of Hippo/YAP pathways 200; 201. 
In this Chapter, we performed in vitro experiments using gain-and-loss of function 
approaches to investigate whether HSPA12B and YAP work together in the regulation 
of angiogenesis.  
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Materials and Methods 
 
Western Blot 
Western blot was performed as described in Chapter 2. The following primary 
antibodies were used in this Chapter: anti-YAP (1:1000 dilution, Cell Signaling 
Technology, 4912s); anti-HSPA12B antibody (1:1000 dilution, gift from Dr. Zhihua Han’s 
lab); anti-β-actin (1:1000 dilution, Cell Signaling Technology, 3700s); anti-GAPDH 
(1:1000 dilution, Cell Signaling Technology, 2118s); anti-Histone3 (1:2000 dilution, 
Novus Biologicals, nb500-171); anti-TBP (1:1000 dilution, Abcam, ab51841). Anti-
GAPDH and anti-β-actin were used as the housekeeping antibodies for cytoplasmic 
protein. Anti-Histone 3 and anti-TBP were used as the housekeeping antibodies for 
nuclear protein.  
 
Immunofluorescent staining 
Hearts from sham and MI WT mice were harvested, cut horizontally, embedded 
in paraffin and cut at a 5 mm thickness. Immunofluorescent staining of paraffin-
embedded heart tissue sections was performed as described above in Chapter 2. The 
primary antibody used in this Chapter was: anti-HSPA12B antibody 91 (1:100 dilution, 
gift from Dr. Zhihua Han (ETSU, Johnson City)). The stained sections were examined 
using Confocal Microscope (Leica Camera, Wetzlar, Germany) and measured by Image 




Total RNA was isolated from cultured cells and mRNA was converted to cDNA 
as mentioned in Chapter 3. The mRNA levels of HSPA12B, YAP, VEGF and Ang1 were 
quantified with the 2 (-ΔΔct) relative quantification method that were normalized to β-
Actin (Applied Biosystems, California, USA). 
 
Endothelial Cell Proliferation Assay, Migration Assay and Matrigel-Based In Vitro 
Angiogenesis Assay 
As mentioned in Chapter 3, EdU incorporation assay and MTT assay, wound-
healing assay, and Matrigel based angiogenesis assay were performed to measure 
endothelial cell proliferative activity, migration and angiogenesis respectively. Images 




Data are expressed as means ± SD. Comparisons of data between groups were 
made using 2 tailed t-test or one-way analysis of variance (ANOVA) followed by Tukey’s 






HSPA12B is Required for MI Induced YAP Cytosolic and Nuclear Expression in the 
Myocardium 
The data above demonstrates that both HSPA12B and YAP are required for 
induction of angiogenesis upon hypoxic challenge. We next sought to investigate 
whether YAP expression could be reconciled with HSPA12B-promoted angiogenesis 
following MI. Figure 20A and B show that the cytosolic and nuclear YAP levels from 
WT MI hearts, but not from eHspa12b-/- MI myocardium, were significantly increased, 
when compared with sham controls. Interestingly, cytosolic HSPA12B levels from WT 
hearts were also markedly increased (112.7%) following MI challenge. Importantly, we 
found for the first time, that HSPA12B is translocated into the nucleus after MI (Figure 
20B and C). The data indicates that endothelial cell HSPA12B can be translocated into 
the nucleus and that endothelial HSPA12B is required for YAP activation and nuclear 
translocation in the response to MI challenge. 
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Figure 20. Endothelial Hspa12b deficiency decreases YAP expression and nuclear 
translocation following MI. WT and endothelial cell specific Hspa12b knockout 
(eHspa12b-/-) mice were subjected to MI or sham surgical operation. The levels of 
HSPA12B and YAP in the cytosol (n=5-6, A) and nucleus (n=4, B) of the myocardium 
were examined by Western blot. GAPDH was used as loading control for cytoplasmic 
protein and Histone 3 was used as loading control for nuclear protein. C, HSPA12B 
nuclear localization was examined by immunofluorescent staining with anti-HSPA12B 
antibody (red). Nucleus were stained with DAPI (blue). n=3/group. Scale bar: 100µm. * 




Endothelial Specific Deficiency of YAP Decreases HSPA12B Expression and Nuclear 
Translocation in the Myocardium Following MI 
To better understand the functions of YAP and HSPA12B in MI-induced 
angiogenesis, we examined HSPA12B levels in the myocardium of eYap-/- MI hearts. 
Figure 21A and B show that HSPA12B expression and the nuclear translocation in the 
myocardium were markedly suppressed in eYap-/- MI mice, when compared with WT MI 
mice. We already observed that YAP expression and nuclear translocation in the 
myocardium were impaired in eHspa12b-/- MI mice (Figure 20A and B). Collectively, the 
data indicates that YAP and HSPA12B may cooperatively regulate angiogenesis in the 
myocardium following MI. 
92 
 
Figure 21. Endothelial Yap deficiency decreases HSPA12B expression and 
nuclear translocation following MI. WT and eYap-/- mice were subjected to MI or 
sham surgical operation. The levels of HSPA12B and YAP in the cytosol (A) and 
nucleus (B) in the myocardium were examined by Western blot (n=4-5). β-actin was 
used as cytosolic loading control and TBP was used as nuclear loading control. * P< 
0.05, ** P< 0.01, *** P< 0.001 compared with indicated group. 
 
HSPA12B is Required for YAP Expression and Nuclear Translocation in Endothelial 
Cells Following Hypoxic Challenge 
To define whether HSPA12B is needed for YAP expression and nuclear 
translocation in endothelial cells, we transfected HUVECs with siRNA for HSPA12B or 
scrambled siRNA which served as a control 24 hours before the cells were subjected to 
hypoxic challenge. Figure 22 shows that hypoxia alone markedly induced both 
HSPA12B and YAP expression and nuclear translocation that are consistent with the 
data observed in the MI hearts (Figure 20A and B). Importantly, silencing of HSPA12B 
by siRNA dramatically suppressed hypoxia-induced YAP expression and nuclear 
translocation (Figure 22). 
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Figure 22. Cooperative regulation of HSPA12B and YAP expression and nuclear 
localization in endothelial cells following hypoxic challenge. HUVECs were 
transfected with siRNA specific for HSPA12B (siHSPA12B) or for YAP (siYAP). 
Scrambled siRNA served as control (siNC). Twenty-four hours after transfection, cells 
were subjected to hypoxia or normoxia. The levels of HSPA12B and YAP in the cytosol 
and the nucleus were examined by Western blot. GAPDH was used as loading control 
for cytoplasmic protein and Histone 3 was used as loading control for nuclear protein. 




In contrast, increased expression of HSPA12B in HUVECs by transfection of Ad-
HSPA12B significantly increased YAP expression and nuclear translocation following 
hypoxic challenge (Figure 23), when compared with control group. The data suggests 
that HSPA12B is needed for YAP expression and nuclear translocation following 
hypoxic challenge. 
Figure 23. HSPA12B upregulates endothelial cell YAP cytosolic and nuclear 
expression after hypoxia. HUVECs were transfected with Ad-HSPA12B or Ad-GFP. 
Twenty-four hours after transfection, cells were subjected to hypoxia or normoxia. The 
levels of HSPA12B and YAP in the cytosol and the nucleus were examined by Western 
blot. GAPDH was used as loading control for cytoplasmic protein and Histone 3 was 
used as loading control for nuclear protein. n=3 independent experiments/group. * P< 




YAP Regulates HSPA12B Expression and Nuclear Translocation in Endothelial Cells 
Following Hypoxia 
In vivo data shows that HSPA12B expression and nuclear translocation are 
markedly impaired in the myocardium of eYap-/- MI mice (Figure 21A and B). To 
explore whether YAP is required for hypoxia promoted HSPA12B expression and 
nuclear translocation, we silenced YAP expression by transfection of HUVECs with 
siRNA for YAP and examined HSPA12B expression and nuclear translocation following 
hypoxic challenge. As shown in Figure 22, silencing of YAP by its siRNA significantly 
attenuated hypoxia induced HSPA12B expression and nuclear translocation. 
Consistently, inhibition of YAP activation with YAP inhibitor, VP, suppressed HSPA12B 
expression and nuclear translocation in the endothelial cells challenged with hypoxia 
(Figure 24A). Importantly, qPCR analysis showed that YAP inhibition also suppressed 
hypoxia induced increase in the levels of HSPA12B mRNA (Figure 24B). Collectively, 
these data demonstrate that YAP is involved in the regulation of HSPA12B expression 




Figure 24. Inhibition of YAP suppresses hypoxia-induced endothelial cell 
HSPA12B expression and nuclear translocation. Endothelial cells were treated with 
YAP inhibitor, Verteporfin (VP, 1 mM), before the cells were subjected to hypoxia. The 
levels of HSPA12B and YAP in the cytosol and the nucleus were examined by Western 
blot (n=3-4, A). GAPDH was used as loading control for cytoplasmic protein and 
Histone 3 was used as loading control for nuclear protein. The mRNA levels of 
HSPA12B and YAP were assessed with qRT-PCR (n=3, B-C). β-Actin was used as 





YAP is Required for HSPA12B Promoted Endothelial Cell Proliferation, Migration and 
Angiogenesis 
To further confirm that YAP participates in HSPA12B promoted endothelial cell 
proliferation, migration and angiogenesis, we transfected endothelial cells with Ad-
HSPA12B 24 hours before the cells were treated with YAP inhibitor (VP). The cells were 
then subjected to hypoxia. Figure 25A and B showed that overexpression of HSPA12B 
promoted cell proliferation following hypoxia was attenuated by YAP inhibition. 
Figure 25. YAP inhibition suppresses HSPA12B induced endothelial cell 
proliferation following hypoxia. HUVECs were transfected with Ad-HSPA12B or Ad-
98 
 
GFP twenty-four hours before the cells were treated with YAP inhibitor, VP (1 mM). The 
cells were then subjected to hypoxia or normoxia. Cell proliferation was evaluated by 
Edu incorporation (A) and MTT assay (B), scale bars: 400µm. n=3 independent 
experiments/group. Comparisons of data between groups were made using 2 tailed t-
test. * P< 0.05, *** P <0.001 compared with indicated group. 
 
In addition, wound-healing assay (Figure 26A) and tube formation assay (Figure 
26B) indicated that inhibition of YAP eliminated HSPA12B enhanced endothelial cell 
migration and angiogenesis respectively. qPCR data showed that YAP inhibition 
markedly downregulated HSPA12B promoted expression of Ang1 mRNA levels by 
56.7% and VEGF by 51.3% (Figure 26C and D), when compared with control group. 
Combined, these data suggest that YAP is required for HSPA12B promoted 
proliferation, migration and angiogenesis following hypoxic challenge. 
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Figure 26. YAP inhibition suppresses HSPA12B induced endothelial cell 
migration and angiogenesis following hypoxia. HUVECs were transfected with Ad-
HSPA12B or Ad-GFP twenty-four hours before the cells were treated with YAP inhibitor, 
VP (1 mM/L). The cells were then subjected to hypoxia or normoxia. A, Cell migration 
was examined by wound-healing assay, scale bars: 400µm. B, Angiogenesis was 
examined by Matrigel assay, scale bars: 400µm. The mRNA levels of Ang1 and VEGF 
were examined by qRT-PCR (C-D). β-Actin was used as the loading control for qRT-
PCR. n=3 independent experiments/group. Comparisons of data between groups were 





In the present study, we observed, for the first time that HSPA12B is translocated 
into the nucleus and promotes endothelial cell proliferation, migration and angiogenesis 
after hypoxia or MI. Our observation indicates a potential mechanism by which 
endothelial HSPA12B regulates angiogenesis. 
 
A recent study showed that heat shock protein 27 is required for YAP activation 
and nuclear translocation in cancer cells 201. Ye et al have reported that inhibition of 
heat shock protein 90 inactivated YAP, thus suppressing lung adenocarcinoma cell 
growth and invasion 200. Collectively, heat shock proteins may participate in the 
activation of Hippo/YAP signaling pathway. Another study reported that YAP nuclear 
translocation is required for blood vessel branching and stabilization 195. Our discovery 
that HSPA12B can translocate into the nucleus and promote angiogenesis, prompted us 
to examine whether YAP would participate in HSPA12B promoted angiogenesis upon 
hypoxia or MI challenge. Interestingly, we found that YAP expression and nuclear 
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translocation were markedly increased in WT MI hearts, but not in the myocardium of 
eHspa12b-/- MI mice. This indicates that endothelial cell HSPA12B is required for YAP 
expression and nuclear translocation in the response to MI challenge. We also 
observed that endothelial cell specific deficiency of Yap markedly impaired cardiac 
angiogenesis via decreased expression of angiogenetic factors following MI. 
Importantly, increased HSPA12B expression and nuclear translocation were observed 
in the myocardium of WT MI mice but not in eYap-/- MI hearts. Our finding indicates that 
YAP is involved in the regulation of HSPA12B expression and nuclear translocation 
following MI. These findings prompted us to ask the question does endothelial 
HSPA12B and YAP cooperatively regulate endothelial cell growth, proliferation and 
angiogenesis? 
 
Interestingly, we observed that HSPA12B nuclear translocation is accompanied 
by YAP activation and nuclear translocation in endothelial cells. The Hippo/YAP 
pathway is a critical player in facilitating cell growth, migration and differentiation 202; 203. 
We found that YAP is required for HSPA12B expression and the nuclear translocation in 
endothelial cells, while HSPA12B is involved in promoting YAP activation and nuclear 
translocation which are associated with endothelial cell proliferation, migration and 
angiogenesis. Together, in vitro and in vivo data indicate the cooperative role of YAP 





CHAPTER 6. HSPA12B IS A TARGET AND CO-ACTIVATOR FOR YAP/TEAD4 IN 




As mentioned above, we discovered that YAP is required for HSPA12B 
expression and nuclear translocation as well as HSPA12B promoted endothelial cell 
proliferation, migration and angiogenesis following hypoxic challenge. In this chapter, 
we investigated how YAP regulate HSPA12B expression and function. When Hippo 
signaling is inactivated, YAP translocates into the nucleus and interacts with 
transcriptional enhanced associated domain family members (TEADs) to regulate 
targeted gene expression together 204; 205. As transcriptional factors, TEADs are 
essential in regulating cardiac and smooth muscle differentiation 206; 207. Joshi and 
colleagues showed that knockdown of TEAD4 impaired the differentiation of 
myofibroblasts both in vivo and in vitro 207. Moreover, TEAD was reported to participate 
in YAP mediated tissue and cell growth 204. We have found that inactivation of YAP by 
VP administration attenuated the mRNA levels of HSPA12B after hypoxia. In this 
Chapter, we tested whether YAP/TEAD4 regulates HSPA12B expression and related 
endothelial cell angiogenesis.  
 
On the other hand, we found that HSPA12B can regulate YAP activation and 
nuclear translocation. In addition, HSPA12B is able to translocate into nucleus after 
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hypoxia, which is accompanied with increased endothelial cell proliferation and 
angiogenesis. Hence, we also examined whether HSPA12B can work as a co-activator 
in regulating YAP associated angiogenesis. 
 
Materials and Methods 
 
Endothelial Cell Transfection and Treatments 
HUVECs were transfected with Ad-GFP or Ad-HSPA12B as described in Chapter 
3. Twenty-four hours after transfection, the cells were subjected to hypoxia or normoxia 
for another 24 hours. In addition, YAP inhibitor verteporfin (VP, 1 mmol/L, Millipore 
Sigma, Missouri, USA) was also employed to suppress YAP activation 1 hour before the 
cells were subjected to hypoxic challenge. In some experiments, administration of 
Cycloheximide (CHX, 100μg/mL, Millipore Sigma, Missouri, USA) or MG132 (12μM, 
Millipore Sigma, Missouri, USA) was performed 1 hour before hypoxia or normoxia to 
inhibit protein synthesis and degradation respectively. 
 
Immunoprecipitation 
Immunoprecipitation was performed as described previously 128. Briefly, 
endothelial cells were seeded in 100mm dishes and lysed using 
radioimmunoprecipitation assay buffer (RIPA buffer) (Table 4). About 200 µg of total 
cellular proteins were incubated with 2 µg anti-HSPA12B, anti-TEAD4 (Abcam, 
ab58310) or anti-YAP antibodies for 12 hours at 4 °C followed by adding 20 µl of pre-
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washed protein A/G-agarose beads (Santa Cruz Biotechnology, Texas, USA). The 
precipitates were washed four times with lysis buffer and boiled in SDS sample buffer 
using dry baths heater. The supernatant was subjected to immunoblotting with 
appropriate antibodies. 
Table 4. Preparation of RIPA Buffer 
Reagent Volume per 50 mL of solution 
50 mM Sodium Chloride  5 mL 
1% Triton X-100 500 µL 
0.5% Sodium deoxycholate 2.5 mL 
0.1% SDS 500 µL 
50 mM Tris, pH 8.0 2.5 mL 
ddH2O Add to 50 mL 
 
Immunofluorescent staining 
For in vitro experiments, processed endothelial cells were washed with phosphate-
buffered saline (PBS) (Thermo Fisher Scientific, Massachusetts, USA) for 3 times and 
fixed with 3.7% formaldehyde (Sigma-Aldrich, Missouri, USA) for 20 minutes. After 
fixation, remove formaldehyde and wash cells 3 times using PBS followed by 
permeabilizing cells with 0.1% Triton® X-100 (Sigma-Aldrich, Missouri, USA) in PBS for 
another 20 minutes. Cells were washed for 3 times and blocked with 3% BSA in PBS for 
30 minutes. Subsequently, cells were incubated with primary antibodies at 4°C overnight 
and washed 3 times with PBS followed by staining with immunofluorescent secondary 
antibodies at room temperature for 90 minutes the next day. After fishing incubating, 
endothelial cells were washed with PBS for 3 times and mounted using mounting media 
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with DAPI. The following primary antibodies were used: anti-YAP antibody (1:100 dilution, 
Cell Signaling Technology, 4912s) or anti-HSPA12B antibody 91 (1:100 dilution, gift from 
Dr. Zhihua Han (ETSU, Johnson City)). The stained cells were examined using Confocal 
Microscope (Leica Camera, Wetzlar, Germany) and measured using Image J software 
(version 1.389, NIH). 
 
Chromatin-immunoprecipitation (ChIP)-qPCR 
ChIP assay was performed using High-Sensitivity ChIP Kit according to the 
manufacturer’s protocol (ab185913, Abcam, Cambridge, United Kingdom). Generally, 
processed endothelial cells were collected and cross-linked, and Working Lysis Buffer 
was added to the cell pellet. After incubating the cells on ice for 10 minutes, the cell 
pellet was vortexed and centrifuged at 3,000 rpm for 5 minutes. Subsequently, the 
supernatant was removed and chromatin was extracted by adding ChIP Buffer and 
incubating on ice. Chromatin lysate was then sheared using probe sonication (Fisher 
Scientific, Massachusetts, USA). Meanwhile, antibody binding reactions was set up by 
diluting specific antibodies (anti-HSPA12B, anti-TEAD4 or anti-YAP antibody) using 
Antibody Buffer in the wells provided in the kit and incubating the wells on a shaker at 
room temperature. Ninety minutes later, antibody binding reactions were removed while 
ChIP reactions were prepared and added to the wells that are bound with antibodies. 
The ChIP reactions were incubated on a shaker at room temperature for additional 90 
minutes, followed by washing the reaction wells with Wash Buffer. RNase A solution 
was then prepared using 1 µL of RNase and 40 µL of DNA Release Buffer and added to 
the reaction wells. The wells were incubated at 42 °C for 30 minutes. Then 2 µL of 
105 
 
Proteinase K was added to the wells and incubated for additional 45 minutes at 60 °C 
followed by 95 °C for 15 minutes in a thermocycler (Thermo Fisher Scientific, 
Massachusetts, USA). The DNA prepared in this way was ready to use for PCR. qPCR 
was performed using SYBR green ReadyMix (Sigma-Aldrich, Missouri, USA) (Table 5) 
and sequences of primers were listed in Table 6. Quantitative real-rime PCR (qRT-
PCR) was conducted using a 4800 RT-PCR machine. 
 
Table 5. Preparation of the ChIP- qPCR Master Mix 
Reagent Volume per single 20 µL reaction 
2X SYBR green ReadyMix 10 µL 
Forward Primer (10 µM) 0.9 µL 
Reverse Primer (10 µM) 0.9 µL 
Nuclease-free H2O 4.2 µL 
DNA 4 µL 
 
Table 6. PCR Primers Used for ChIP Analysis 
Names Sequences (5'->3') 
HSPA12B Forward Primer TGCTGATATGGCGTGGAGAC 
HSPA12B Reverse Primer CACCCCCTTCTGGTCAGTTC 
YAP Forward Primer GCGGATATGAACATGGCTGCT 
YAP Reverse Primer TGGGCAAAGTTCCTATGCTG 
CTGF Forward Primer AGGCTTTTATACGCTCCGGG 





Total RNA was isolated from cultured cells and mRNA was converted to cDNA 
as mentioned in Chapter 3. The mRNA levels of HSPA12B, YAP, MFAP5 and CTGF 
were quantified with the 2 (-ΔΔct) relative quantification method that were normalized to 
β-Actin (Applied Biosystems, California, USA). 
 
Western Blot 
Western blot was performed as described in Chapter 2. The following primary 
antibodies were used in this Chapter: anti-YAP (1:1000 dilution, Cell Signaling 
Technology, 4912s); anti-HSPA12B antibody (1:1000 dilution, gift from Dr. Zhihua Han’s 
lab); anti-β-actin (1:1000 dilution, Cell Signaling Technology, 3700s); anti-GAPDH 
(1:1000 dilution, Cell Signaling Technology, 2118s); anti-TBP (1:1000 dilution, Abcam, 
ab51841). Anti-GAPDH and anti-β-actin were used as the housekeeping antibodies for 




Data are expressed as means ± SD. Comparisons of data between groups were 
made using 2 tailed t-test or one-way analysis of variance (ANOVA) followed by Tukey’s 






Hypoxia Induces an Interaction Between YAP and HSPA12B 
The biologically cooperative effects of YAP and HSPA12B in regulating 
endothelial cell function during hypoxia leads us to investigate whether YAP and 
HSPA12B physically interact with each other during hypoxia. HUVECs were subjected 
to hypoxia or normoxia which served as control. Cellular proteins were isolated for 
immunoprecipitation with anti-YAP antibody followed by immunoblot with anti-HSPA12B 
antibody. Figure 27A showed that hypoxia significantly induced an interaction between 
YAP and HSPA12B as evidenced by HSPA12B appearing in the immunoprecipitation 
with YAP antibody. We also performed the immunoprecipitation with anti-HSPA12B 
antibody followed by immunoblot with anti-YAP antibody. Reciprocally, YAP appeared in 
the immunoprecipitate with anti-HSPA12B antibody (Figure 27B). To further support 
our finding, immunofluorescent staining was performed with anti-YAP (red color) and 
HSPA12B (green color) antibodies. As shown in Figure 27C, there was significant 
cytoplasmic and nuclear co-localization of YAP and HSPA12B following hypoxic 
challenge. However, inhibition of YAP with YAP inhibitor, VP, suppressed YAP nuclear 




Figure 27. HSPA12B interacts with YAP in endothelial cells following hypoxic 
challenge. HUVECs were subjected to hypoxia or normoxia for 24 hours. Cells were 
harvested for the isolation of cellular proteins. A, Immunoprecipitation was performed 
with anti-YAP antibody followed by immunoblot with anti-HSPA12B antibody (n=2). B, 
Immunoprecipitation was performed with anti-HSPA12B antibody followed by 
immunoblot with anti-YAP antibody (n=2). GAPDH was used as loading control. C, 
HUVECs were treated with or without Verteporfin (VP, 1 mM) before subjected to 
hypoxia. Immunostaining were performed with anti-HSPA12B (green) and anti-YAP 
(red) antibodies (n=2), scale bar: 10µm. GAPDH was used as loading control. 
 
HSPA12B is a YAP/TEAD4 Target in HUVECs 
Since we observed that YAP inhibition decreased HSPA12B mRNA levels 
(Figure 24B), we next investigated whether HSPA12B is a direct transcriptional target 
of YAP in HUVECs. YAP controls gene transcription via binding to TEAD around the 
promoter or enhancer of target genes 208; 209. Therefore, we searched for and identified 
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TEAD4-binding motif in the HSPA12B gene enhancer regions. Chromatin 
immunoprecipitation (ChIP) was performed to validate the potential binding sites of 
YAP/TEAD4 protein in the HSPA12B gene enhancer region. As shown in Figure 28, 
ChIP assay using anti-YAP or anti-TEAD4 indicates that both YAP and TEAD4 
specifically associated with the enhancer region of HSPA12B gene, which can be 
induced by hypoxia. These data suggest that HSPA12B is a YAP/TEAD4 direct target in 
HUVECs. 
Figure 28. HSPA12B is a YAP/TEAD4 target in HUVECs. HUVECs were subjected to 
hypoxia or normoxia for 24 hours. ChIP in HUVECs with indicated antibodies (YAP or 
TEAD4) followed by qPCR using primers specific for indicated regions of HSPA12B. 
n=4 independent experiments/group. * P< 0.05, ** P <0.01, compared with indicated 
group. 
 
HSPA12B is a Co-activator in YAP/TEAD4-Regulated Angiogenesis 
We have observed that HSPA12B could translocate into the nucleus. Next, we 
investigated whether there is an interaction between HSPA12B and TEAD4. Cellular 
proteins were isolated for immunoprecipitation with anti-TEAD4 antibody followed by 
immunoblot with anti-HSPA12B antibody. Figure 29A showed that hypoxia induced the 
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interaction between TEAD4 and HSPA12B. To determine whether nuclear HSPA12B 
could act as a co-activator of YAP/TEAD4 complex to regulate target gene transcription, 
we first examined the mRNA levels of YAP/TEAD4 target genes MFAP5 and CTGF, 
which are related to angiogenesis and proliferation respectively 168. As expected, the 
mRNA expression of MFAP5 and CTGF were enhanced remarkably by overexpression 
of HSPA12B alone which can be abolished by YAP inhibitor VP administration (Figure 
29B and C). ChIP assay also revealed that HSPA12B co-localizes with YAP and 
TEAD4 at the promotor region of CTGF (Figure 29D). These data indicate that 
HSPA12B and YAP/TEAD4 form a complex that synergistically activates target genes 
involved in cellular proliferation and angiogenesis. 
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Figure 29. HSPA12B and YAP/TEAD4 form a complex that activates target genes 
involved in cellular proliferation and angiogenesis. HUVECs were subjected to 
hypoxia or normoxia for 24 hours. Cells were harvested for the isolation of cellular 
proteins. A, Immunoprecipitation was performed with anti-TEAD4 antibody followed by 
immunoblot with anti-HSPA12B antibody (n=2). GAPDH was used as loading control. B-
C, HUVECs were transfected with Ad-HSPA12B or Ad-GFP. Twenty-four hours after 
transfection, cells were treated with or without Verteporfin (VP, 1 mM) and subjected to 
hypoxia or normoxia. The mRNA levels of MFAP5 (n=3) and CTGF (n=3-4) were 
examined by qRT-PCR. β-Actin was used as loading control. D, HUVECs were 
subjected to hypoxia or normoxia for 24 hours. ChIP in HUVECs with indicated 
antibodies (HSPA12B, YAP or TEAD4) followed by qPCR using primers specific for 
indicated regions of CTGF. n=4 independent experiments/group. * P< 0.05, ** P <0.01, 
*** P <0.001 compared with indicated group. 
 
To better understand the underlying molecular mechanism of HSPA12B 
mediated YAP regulation, we examined the possibility of HSPA12B protein with YAP 
gene regulatory elements. Surprisingly, we detected a binding activity of HSPA12B 
protein and YAP gene enhancer, which could be induced by hypoxic challenge. (Figure 
30A). In parallel, qPCR data showed hypoxia upregulated the mRNA levels of 
HSPA12B and YAP (Figure 30B and C). Importantly, increased expression of 
HSPA12B by Ad-HSPA12B transfection markedly upregulated YAP mRNA levels 
induced by hypoxia (Figure 30B and C), indicating that HSPA12B serves as a 
transcriptional co-activator in regulating YAP expression. 
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Figure 30. HSPA12B is a co-activator in YAP-regulated angiogenesis. A, HUVECs 
were subjected to hypoxia or normoxia for 24 hours. ChIP in HUVECs with indicated 
antibodies (HSPA12B or YAP) followed by qPCR using primers specific for indicated 
regions of YAP. n=3 independent experiments/group. B-C, HUVECs were transfected 
with Ad-HSPA12B or Ad-GFP. Twenty-four hours after transfection, cells were 
subjected to hypoxia or normoxia. The mRNA levels of HSPA12B and YAP were 
examined by qRT-PCR. β-Actin was used as loading control for qRT-PCR. n=3 
independent experiments/group. * P< 0.05, ** P <0.01, *** P <0.001 compared with 
indicated group. 
 
HSPA12B Stabilizes YAP Protein 
Furthermore, we treated endothelial cells with cycloheximide (CHX), a protein 
translation inhibitor 210. HUVECs were transfected with Ad-HSPA12B or Ad-GFP 
followed by administration of CHX. We observed that CHX administration significantly 
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decreased HSPA12B and YAP cytosolic and nuclear expression following hypoxic 
challenge (Figure 31). However, transfection with Ad-HSPA1B reversed YAP 
expression and nuclear translocation remarkably, indicating that upregulation of 
HSPA12B stabilized YAP protein. 
Figure 31. Overexpression of HSPA12B reverses YAP cytosolic and nuclear 
expression decreased by cycloheximide (CHX) administration following hypoxic 
challenge. HUVECs were transfected with Ad-HSPA12B or Ad-GFP. Twenty-four hours 
after transfection, the cells were treated with or without CHX (100 μg/mL) before 
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hypoxia. The levels of HSPA12B and YAP in the cytosol and the nucleus were 
examined by Western blot (n=3-4). β-actin was used as cytosolic loading control and 
TBP was used as nuclear loading control. * P< 0.05, ** P <0.01, *** P <0.001 compared 
with indicated group. 
 
HSPA12B Prevents YAP from Degradation 
In addition, we also treat endothelial cells with MG132, a proteasome inhibitor 211, 
to confirm whether HSPA12B can prevent the degradation of YAP. Figure 32 showed 
that administration of induces YAP cytosolic and nuclear expression following hypoxia, 
while overexpression of HSPA12B by Ad-HSPA12B transfection further increased 
MG132 induced YAP expression and nuclear translocation, suggesting that HSPA12B 
overexpression promotes YAP transcription.  
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Figure 32. Overexpression of HSPA12B increased MG132 induced YAP 
expression and nuclear translocation after hypoxia. HUVECs were transfected with 
Ad-HSPA12B or Ad-GFP. Twenty-four hours after transfection, the cells were treated 
with or without MG132 (12μM) before hypoxia. The levels of HSPA12B and YAP in the 
cytosol and the nucleus were examined by Western blot. β-actin was used as cytosolic 
loading control and TBP was used as nuclear loading control. n=3 independent 
experiments/group. * P< 0.05, ** P <0.01, *** P <0.001 compared with indicated group. 
 
Together, our data demonstrates that binding to HSPA12B stabilizes YAP protein 
and prevent YAP from degradation. Moreover, HSPA12B functions as a novel co-
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Our findings reveal a previously unrecognized role for endothelial cell HSPA12B 
in the regulation of angiogenesis, i.e. endothelial HSPA12B and YAP cooperatively 
regulate angiogenesis. Interestingly, there is an interaction between YAP and HSPA12B 
in endothelial cells after hypoxia in that YAP was found in the HSPA12B 
immunoprecipitant. Reciprocally, HSPA12B also appears in YAP immunoprecipitant. It 
is possible that the association of YAP and HSPA12B is required to facilitate 
YAP/HSPA12B activation and nuclear translocation for the process of endothelial cell 
angiogenesis. 
 
To further investigate the mechanisms by which YAP and HSPA12B 
cooperatively regulate angiogenesis, we performed ChIP assay and found that 
HSPA12B is a target gene of YAP/TEAD4 and the binding site is located at the end of 
the HSPA12B gene. Galli et al claim that YAP and TEAD binding is restricted to distal 
elements in the genome 212, which is consistent with our observation. A large fraction of 
the distal elements of TEAD is overlapped with H3K27ac active enhancer mark 213, 
which further confirmed the possibility of binding of TEAD4 and HSPA12B gene. Since 
HSPA12B can translocate into the nucleus after MI or hypoxic challenge, we next 
117 
 
examined whether HSPA12B would work as a co-effector at transcriptional level during 
YAP/TEAD4 regulated angiogenesis. Indeed, we detected an interaction between 
TEAD4 and HSPA12B. Additionally, we discovered that overexpression of HSPA12B 
upregulated the mRNA expression of YAP as well as YAP target gene CTGF and 
MFAP5 following hypoxia. In accordance, ChIP assay revealed a binding activity of 
HSPA12B protein and YAP gene enhancer in endothelial cells. Moreover, HSPA12B 
overexpression also reversed YAP expression and activation that were suppressed by 
protein translation inhibition using CHX. Administration of a proteasome inhibitor, 
MG132, showed that HSPA12B can promote YAP transcription. Therefore, we revealed 
an important role of HSPA12B in the regulation of YAP expression. Our data suggests 
two possible mechanisms by which HSPA12B regulates YAP expression. Firstly, 
HSPA12B forms a cluster with YAP/TEAD4 and positively activates YAP at 
transcriptional level following hypoxia to induce endothelial cell angiogenesis. Secondly, 
HSPA12B can stabilize YAP and abrogate the degradation of YAP.   
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CHAPTER 7. CONCLUSION 
 
In conclusion, the present study has revealed a novel mechanism by which 
endothelial cell HSPA12B regulates cardiac angiogenesis after MI. As shown in Figure 
33, we demonstrated that endothelial cell HSA12B is translocated into the nucleus 
accompanied by YAP activation and nuclear translocation in endothelial cells in both in 
vivo and in vitro studies. Interestingly, we discovered that HSPA12B and YAP 
cooperatively regulate endothelial cell proliferation and angiogenesis following hypoxic 
challenge or MI. Of note, HSPA12B is a target gene of YAP and YAP is needed for 
HSPA12B promoted angiogenesis. On the other hand, YAP-targeted HSPA12B works 
as a transcriptional co-activator to induce YAP activation and nuclear translocation in 
the regulation of endothelial cell proliferation, migration and angiogenesis after hypoxia.  
 
In the future study, we are going to examine the therapeutic potential of 
HSPA12B for cardiac ischemic injury. We have found that hypoxia promotes HSPA12B 
expression and release from endothelial cells via exosomes. We will transfect 
endothelial cells with Ad-HSPA12B and isolate exosomes from cultured medium. We 
will then deliver HSPA12B containing exosomes to the myocardium through the right 
carotid artery immediately after induction of MI in WT and eYap-/- mice and test whether 
delivery of HSPA12B will attenuate cardiac dysfunction after MI. 
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Figure 33. Endothelial cell HSPA12B and YAP cooperatively regulate 
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